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Personalized approaches have shown great potential to transform modern medicine.
As challenging as it may sound, we are making tremendous progress with the help of data
sciences and machine learning. Two fundamental tasks in data sciences are prediction and
inference. In this dissertation, I proposed to address these two tasks using deep learning
approaches in the setting of personalized medicine. First, I developed a novel framework to
estimate individualized treatment effects (ITE), which quantified the variation in response to
the same treatment among patients with heterogeneous profiles. The ITE estimation has the
potential to replace the one-size-fits-all average treatment effects (ATE) commonly used in
clinical practice and provides more accurate patient-specific treatment guidance. Second, I
developed a statistical test to determine pairwise causation between two sets of continuous
variables. Despite of the massive data available, the primary methods to determine causation
clinically are through randomized controlled experiments and animal studies, which are
highly inefficient or sometimes even infeasible. With this new statistical test, we were able to
draw causal conclusions from observational data instead of experimental data alone, which

was beneficial in terms of understanding underlying disease mechanisms. Statistical
simulation was conducted to demonstrate the validity and accuracy of the proposed methods.
Last but not least, I applied the developed methods on real-life datasets to demonstrate their
usage. The TCGA lung cancer dataset was used to estimate ITE for patients with complex
covariate structure. I also performed an end-to-end causal discovery for Alzheimer’s disease
using the medical images from the ADNI dataset. The results indicate deep learning based
approaches offer great flexibility and deep insights for biomedical data, which will help us
bridge the gap in precision medicine.
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BACKGROUND
1. Literature Review
Over the past few decades, we have witnessed the rise of precision medicine, which
was defined as ‘an emerging approach for disease treatment and prevention that takes into
account individual variability in genes, environment and lifestyle for each person’ by the
National Institutes of Health (NIH). Two major tasks in statistics that are relevant to
precision medicine are prediction and inference. Prediction focuses on forecasting future
events based on observed ones, whereas inference emphasizes understanding the data
generating process or causes of observed events. When it comes to precision medicine, we
not only want to predict individualized risks/effects, but also hope to understand the
underlying causes of diseases and the diverse manifestations observed on individuals.
Thanks to the increasing availability of data in this digital era and rapid development in deep
learning approaches, we have been moving closer to the goal of individualized risk prediction
and conducting causal discoveries in settings that are not limited to randomized clinical trials.
1.1 Neural Networks
Deep learning is a subfield of machine learning, which centers around neural
networks. As the name suggests, neural networks were motivated by the neural system of
human beings that is in charge of processing signals and transmitting information to our
brains (Figure 1). As popular as it may sound nowadays, the concept of neural networks
dates back to 1940s. In 1943, Walter Pitts and Warren McCulloch designed the ‘thresholded
logic unit’, which was a step function that worked in a similar way as the human neuron did
by employing a threshold (McCulloch & Pitts, 1943). Alan Turing first described the ‘Turing
1

test’, which listed criteria to determine if machine could be considered as intelligent in his
paper published in 1950 (Machinery, 1950). However, the perceptron model proposed by
Frank Rosenblatt in 1958 was considered as the building blocks of neural networks
(Rosenblatt, 1958). The Rosenblatt perceptron was a binary single neuron model to classify
two linearly separable classes. It output 1 if the weighted average of input plus bias was
positive, and output -1 otherwise. Despite of the impressive performance of perceptron,
Marvin Minsky and Seymor Papert pointed out in 1969 that the perceptron was theoretically
impossible to learn non-linear functions (Minsky & Papert, 2017), which marked the start of
the first artificial intelligence (AI) winter.
It was not until the development of backpropagation in 1986 that the scientific
community started to feel amazed again by the potential of neural networks with stacked
perceptrons and activation functions to allow for non-linearity. The backpropagation learning
algorithm worked by taking the derivatives of the network’s loss functions and backpropagate the errors to adjust the weights and biases in the network (Rumelhart, Hinton, &
Williams, 1986). In 1991, Kurt Hornik proved the universal approximation capabilities of
multilayer feedforward networks (Hornik, 1991). Despite of a few early successes, neural
networks failed to scale to larger problems, mainly due limited computing power, which
brought another setback for AI from late 1980s to early 1990s.
Thanks to the increasing computing power and innovative designs such as deep belief
networks (Hinton, 2009), neural networks with multiple hidden layers began to attract more
and more attention, and the name ‘deep learning’ was introduced as a rebranding of neural
networks in 2006. In recent years, the use of graphics processing units (GPUs) and various
2

regularization techniques such as dropout (Srivastava, Hinton, Krizhevsky, Sutskever, &
Salakhutdinov, 2014) and batch normalization (Ioffe & Szegedy, 2015) have tremendously
stabilized and speeded up the training of neural networks with more advanced designs
including the convolution neural networks (CNN), recurrent neural networks (RNN) and
residual neural networks (ResNet). In addition, the application of deep learning algorithms in
medicine has achieved great success, producing results comparable or surpassing the
traditional machine learning methods (Cheng et al., 2016; Esteva et al., 2017).
1.2 Convolutional Neural Networks
Convolutional neural networks (CNNs) was one of the most widely used deep
learning techniques in the field of computer vision. This concept was first introduced by
Kunihiko Fukushima in 1980 as neocognitron, where he presented the early forms of
convolutional layers and down-sampling layers (Fukushima, 1980; Schmidhuber, 2015).
However, Fukushima updated weights using WTA-based unsupervised learning rules
(Fukushima, 2013) instead of backpropagation and the down-sampling technique he used
were spatial averaging, in contrast to max pooling, which are more popular nowadays. In
1990, Yann LeCun published the LeNet, which achieved 1% error rate on zip code digits
with minimal preprocessing (LeCun et al., 1990). Later he published a series paper
improving the design of CNNs and expanding the applications (LeCun, Bottou, Bengio, &
Haffner, 1998; LeCun, Haffner, Bottou, & Bengio, 1999). The ImageNet project, which was
first presented in 2009, was considered a milestone in the development of CNNs. ImageNet
has been a growing database which holds millions of images with annotations obtained from
crowdsourcing and this massive amount of data enabled CNNs with much deeper
3

architecture. Krizhevsky et al. came up with the AlexNet that brought the error rate down by
more than 10% in the 2012 ImageNet Large Scale Visual Recognition Challenge (ILSVRC),
where they showed that the depth of the network was crucial for its top
performance(Krizhevsky, Sutskever, & Hinton, 2012). CNNs have since evolved rapidly,
with applications in various filed such as automatic driving, facial recognition and medical
diagnosis.
The great potential of CNNs has drawn a lot of attention from the medical imaging
community, resulting an unprecedented shift in the ways to extract information. For
example, Esteva et al. presented a CNN classification of skin cancer, which had performance
comparable to dermatologists (Esteva et al., 2017). A team from Google relied on CNNs to
learn features from retinal fundus images to predict age, gender and major cardiac events
with satisfactory results (Gulshan et al., 2016). Kermany et al. established CNNs with
transfer learning to screen patients with common treatable blinding retinal diseases and
demonstrated performance at the level of human experts, among many others (Kermany et
al., 2018).
Despite the great success of CNNs in medical imaging, they have been criticized as
being ‘black box’ methods, which were non-transparent and difficult to interpret to medical
professions and patients, greatly limiting the usage of such techniques. A lot of research
efforts have been put into creating interpretable CNNs. The most straight forward method
would be looking at the layer activations by plotting the activation maps for each filter
(Stanford, 2019). Another method would be visualizing the weights/filters of the first few
layers in a CNN, where relatively smooth patterns should be observed if the network
4

converges well (Stanford, 2019). Google has also made their contribution to interpretable
CNNs by proposing using optimization and regularization for feature visualization (Olah,
Mordvintsev, & Schubert, 2017). In addition, spatial embedding methods such as t-SNE can
be used to embed high-dimensional vector from the last layer before classification into twodimensional vector for each image and all the embedded images can be visualized in a grid.
Similarities in embedded images indicate that CNNs ‘see’ the images as close ones (Stanford,
2019). Perhaps the most intuitive method would be the occlusion heat maps (Zintgraf, Cohen,
Adel, & Welling, 2017). These are created by iterating over regions of the image, removing
the regions one at a time and assessing how the prediction probabilities change for the class
of interest. Variations of this method has been applied to images of everyday objects, but
much less commonly in medical research involved CNNs.
1.3 Auto-Encoders
Auto-encoder is one of the most commonly known unsupervised-learning techniques
(Kingma & Welling, 2013). It consists of two part, one encoder and one decoder. The
encoder takes in the data 𝑥, passes through any hidden layers, and compresses it into a latentspace representation ℎ. The encoder performs the transformation ℎ = 𝑓(𝑥). The decoder
treats ℎ as input, passes through any hidden layers, and reconstruct the output in the input
space. Mathematically, the decoder performs the transformation 𝑦 = 𝑔(ℎ). The cost function
can defined as the mean squared error between 𝑥 and 𝑦. An auto-encoder is optimized when
𝑥 and 𝑦 are as close as possible and thus the training is carried out by minimizing the mean
squared error loss function.
5

There have been many variations of auto-encoders. One of the most popular types is
the variational autoencoder (VAE) (Kingma & Welling, 2013). Contrast to the classic autoencoder where a single scalar value is output by the encoder for each encoded dimension,
VAE provides a probabilistic way to learn the data representation in the latent space. The
encoder of VAE (also called the recognition model for VAE) describes a probability
distribution for each encoded dimension, whereas the decoder (also called the generative
model) tries to reconstruct the input based on a continuous and more smoothed latent space
representation (Jordan, 2018). In order to accommodate different types of data and tasks,
researchers have also been using convolutional auto-encoders for images, recurrent or long
short term memory (LSTM) auto-encoders for text mining and signal enhancement, and
regularized auto-encoders for tasks such as classification and denoising.
The concept of auto-encoder was first proposed around 1987 as a method for
unsupervised pre-training of neural networks by DH Ballard (Ballard, 1987), they have been
mostly used to perform data denoising and dimension reduction/feature learning over the past
few years. Vincent et al. first proposed denoising autoencoders (DAE) to extract and
compose robust features (Vincent, Larochelle, Bengio, & Manzagol, 2008), which has been
further extended and applied to image denoising, language generation and signal
enhancement (Freitag & Roy, 2018; Gondara, 2016; P. Xiong et al., 2016). Auto-encoders
have also achieved a great success in automatic feature engineering. They are not only
capable of learning linear transformations like the principal component analysis does, but
also good at capturing non-linear transformations, with the help of non-linear activation
functions. For example, Dong et al. used auto-encoder regularized network to perform
6

driving style representation learning (Dong, Yuan, Yang, Li, & Zhang, 2017), which
outperformed other state-of-art methods; LSTM autoencodersss achieved a great success in
learning video representations, which was proven to be very helpful when the learned
representations were later used in other supervised learning problems (Srivastava, Mansimov,
& Salakhudinov, 2015); Auto-encoders have also been applied to speech waveforms to learn
meaningful latent representation of speech, generating results comparable to the top entries in
the ZeroSpeech 2017 unsupervised acoustic unit discovery task (Chorowski, Weiss, Bengio,
& van den Oord, 2019).
1.4 Generative Adversarial Network
Generative adversarial network (GAN) was first introduced by Ian Goodfellow in
2014 (Goodfellow et al., 2014). GAN is an innovative framework which consists of two
neural networks, a generator and a discriminator, that are trained simultaneously in an
adversarial fashion. The generator is aimed to generate data that comes from the same
distribution as the training data, whereas the discriminator learns to distinguish whether a
sample comes from the training data or the generator. This competition improves both the
generator and the discriminator, resulting in a stage where the generated data is
indistinguishable from the real training data. GAN framework does not need any assumptions
about the underlying distributions or rely on Markov chains for inference, which makes it
extremely valuable for many applications. Another remarkable feature is that once GAN
learns about the underlying distribution of the training data, it is able to generate data that has
not been seen in the training set.
7

Shortly after the publication of the vanilla version of GAN, Mehdi Mirza and Simon
Osindero introduced the conditional GAN (CGAN, Figure 2.), where the framework was able
to learn distributions conditioned on another variable (Mirza & Osindero, 2014). Radford et
al. replaced the simple neural networks with CNNs in both discriminators and generators and
proposed the deep convolutional generative adversarial networks (DCGANs), which have
been widely applied in computer vision (Radford, Metz, & Chintala, 2015). Despite the
successful stories of GANs, they were notoriously hard to train due to problems like nonconvergence, mode collapse, diminished gradients and sensitivity to hyper-parameters.
Arjovsky et al. introduced the Wassterstein GAN (WGAN) as a remedy to these problems by
using the Wassterstein distance in the optimization (Arjovsky, Chintala, & Bottou, 2017);
Gulrajani et al. proposed to add gradient penalty to the loss function of WGAN, further
improving the performance of GANs (Gulrajani, Ahmed, Arjovsky, Dumoulin, & Courville,
2017). Meanwhile, GANs have been considered as one of the major approaches in
unsupervised learning and many variations have been published such as Coupled GAN (M.Y. Liu & Tuzel, 2016), Auxiliary Classifier GAN (Odena, Olah, & Shlens, 2017),
DiscoGAN (Kim, Cha, Kim, Lee, & Kim, 2017) and Boundary Seeking GAN (Hjelm et al.,
2017).
1.5 Causal Inference
1.5.1 Causation vs. Association
Causal inference has been a fundamental task in scientific research as well as
philosophical studies. Conceptually speaking, causal inference aims to determine if there
8

exists a causal connections between variables based on their occurrences in response to the
change of other variables. The first task in causal inference is to tell the difference between
causation and association. As human beings, we grasp these concept well without realizing it.
For example, we know that carrying an umbrella kept us dry in the rain from the past
experience. Had we not carried an umbrella, we would have become wet in the rain.
Therefore, we conclude that carrying an umbrella is a cause for staying dry in the rain. In
contrast, there is a positive correlation between ice cream sales and the number of sunglasses
sold, but we would never say increasing ice cream sales is a cause for more sunglasses sold.
As J. Pearl has pointed out, the basic distinction between causation and association is
coping with change, or to put it in another way, coping with interventions (Pearl, 2009).
Causation is different from association by taking a step further to understand the dynamics
under changing conditions/different interventions, whereas association only emphasizes
making inference under static conditions (Pearl, 2009).
To define a causal effect on a population level, there are two sets of mathematical
notations that encode the same meaning. The first set of notations was introduced by Judea
Pearl, called ‘do- Calculus’, where 𝐸[𝑌|𝑑𝑜(𝑇 = 0)] ≠ 𝐸[𝑌|𝑑𝑜(𝑇 = 1)] indicates causation
between T and Y, assuming there is no confounding. 𝑑𝑜(𝑇 = 𝑡) means an intervention to
artificially force the variable T to take the value t. This is different from the conditional
probability, which was based on static conditions. For example, let 𝑝(𝑌|𝑇) stands for the
distribution of temperature Y when thermometer displays a reading of T. We could observe
pairs of Y and T at random times. Knowing T will give me some information about Y.
9

However, 𝑃(𝑌|𝑑𝑜(𝑇 = 𝑡)) means that we manually force the reading of the thermometer to t,
but this will not affect the actual temperature to change. In this example, 𝑃(𝑌|𝑑𝑜(𝑇 = 𝑡))
does not depend on the value of t here, and it should be the same as 𝑃(𝑌).
Another framework would be counterfactuals proposed by Rubins (Hernán MA,
2019). It stemmed directly from the setting of randomized controlled trails. In a randomized
trails, a participant will only be randomized to a single treatment group and the observed
outcome is called the factual outcome. A counterfactual outcome is defined as what would
have happen had the participant been randomized to a different treatment group. The average
causal effect in population under this framework is defined as 𝐸[𝑌

] ≠ 𝐸[𝑌

], if the

treatment T is binary.
In the field of artificial intelligence, causation is generally reflected in the generating
mechanism for the observed data. In contrast to association, causation is less of interest
when the purpose is forecasting/prediction and there is a large amount of data. Given enough
amount of data, deep learning algorithms are capable to capture rich information that is
predictive of the outcome, without the need to worry about the underlying mechanism. For
example, gender and age may have large predictive power for certain types of cancer, but we
would not reach the conclusion that they are causes for the disease. However, when the
amount of data is limited, which is common in the medical setting, understanding the data
generating process is crucial and can help us get further insights about disease etiology.
1.5.2 Directed Acyclic Graphs

10

The most commonly used way to describe the causal connections between variables is
through directed acyclic graphs (DAG). ‘Directed’ implies the connections in the graph have
directions and ‘acyclic’ means that there are no cycles in the graph: you can never go back to
the same variable where you start by following the directions of the arrows. The variables
here have another name called ‘nodes’ and the arrows are referred as ‘directed edges’ in a
DAG. Despite the fact that DAG have implications in many applications such as structural
equation models (SEM) and Bayesian networks, I will use causal DAG and DAG
interchangeably in this dissertation. Causal DAG requires that the common causes of any pair
of variables are also in the graph (Hernán MA, 2019). Causal DAG is not only useful to
illustrate the causal assumptions for observed data, but also encodes the associations between
variables. In fact, causation always leads to association, but the reverse is not true.
Figure 3 is a DAG for randomized controlled trials (RCTs), which is considered as
the gold standard to establish causation. For example, a pharmaceutical company is interested
in determine the effect of a new drug T on the survival time for cancer patients. They
randomize the patients to the drug and a type of placebo and compare the survival time for
the two groups of patients. If the patients randomized to the new drug have significantly
longer average survival time compared to patients in the placebo group, they may conclude
that the new drug causes the longer survival and thus it is effective.
Figure 4 demonstrate a common DAG used for observational studies. For example, X
denotes social economic status; T stands for insurance plans; Y is health care expenditure.
Social economic status determines which type of insurance is a person will purchase, and
insurance type has a causal effect on health care expenditure, but social economic status also
11

has direct causal effect on a person’s health care expenditure. In this scenario, social
economic status can be considered as a confounder for the causations between insurance and
healthcare expenditure. If we assume there is no residual confounding, which means there is
no variable other than social economic status that is the common cause of insurance and
health care expenditure, we will be able to infer the direct causal effect of T on Y if and only
if we block the backdoor path from T to Y. In statistics, we achieve this blocking by
adjusting or controlling X in causal models. This is illustrated in a DAG by putting a box
around X. After blocking the backdoor path from T to Y, we can safely erase the node X and
the edges coming from X. In this way, we are able to get the same DAG in Figure 2. This
type of analysis is called observational causal inference, which aims to determine causations
from observational data when RCTs are impractical or unethical. For example, when we are
interested in determine if a certain gene cause a type of cancer, it is impossible for us to
randomize genes to different group of people; if we would like to study the effect of smoking
on lung cancer, it is unethical to randomly assign participants to a smoking group where they
are required to smoke heavily.
1.5.3 Average Treatment Effect
Observational causal inference emphasizes to draw causal conclusions using
observational data. This can be considered as a type of transfer learning, where we learn from
the observational data and transfer the knowledge into a RCT setting as illustrated in Figure
2. Causal effects can be defined on two levels - the population level and the individual level,
corresponding to average treatment effect (ATE) and individualized treatment effect (ITE).
12

Classical work focused more on estimating ATE. One of the most commonly used
methods to estimate ATE from observational studies is propensity score method (Austin,
2011). Propensity score is the probability of getting the treatment for each individual given
the covariate profile. It is a balancing score, which is designed as a way to block the
backdoor path from the treatment to the outcome through confounders (i.e. the treatment and
the confounders are independent conditional on propensity scores), so that observational
studies can mimic the design of RCT, assuming the propensity score is correctly estimated.
After obtaining the propensity scores, covariates should distribute identically within the same
levels of propensity scores. There are various ways to incorporate propensity score in the
estimation of ATE. The first way would be to treat propensity score as a covariate in the
regression models (Elze et al., 2017). Depending on the type of outcomes, regression models
are built with treatment and propensity score as two covariates in the model. Transformations
or higher order terms for propensity scores may be needed depending the nature of causation.
In contrast to this method, the other three methods separate propensity score from the
analysis and consider it more as a study design feature (Austin, 2011). For example, study
sample could be matched based on their propensity score, and the analysis could be carried
out as a matched study (Dehejia & Wahba, 2002; Rosenbaum & Rubin, 1985). Another
method would be stratification by propensity score, where the entire sample is divided into
multiple strata based on propensity scores. Regression models are built within each stratus
and later pooled together to get an overall ATE (Lunceford & Davidian, 2004; Rosenbaum &
Rubin, 1984). In addition, Rosenbaum proposed the inverse probability of treatment
weighting (IPTW) using propensity score. Each subject is assigned a weight defined by 𝑤 =
13

+

, where Ti stands for treatment assignment (0 or 1) for subject i, and S indicates the

propensity score for that subject. By applying IPTW, we create a pseudo-population where
ATE for this population can be estimated directly using regression models (Austin & Stuart,
2015; Rosenbaum, 1987). Structural equation models and Bayesian networks can also be
used to estimate the average treatment effect, but they require the causal Markov assumption
and the causal faithfulness assumption to hold for valid inference (Spirtes & Zhang, 2016).
1.5.4 Individualized Treatment Effect
Given the increasing amount of data and the heterogeneous effects of treatments in
medical setting (Angrist, 2004; Kravitz, Duan, & Braslow, 2004), individualized treatment
effect (ITE) has received more and more attention. ITE estimation is most straightforward in
the framework of counterfactuals, where the difference between the expected factual
outcome and the expected counterfactual is considered as the treatment effect for a subject,
assuming a binary treatment. Propensity score based methods can be adapted to estimate ITE
by predicting the counterfactuals using the regression models adjusting for propensity score
(Dehejia & Wahba, 2002). However, they replies on parametric assumptions and thus have
limited usage. Porter et al., presented the targeted maximum likelihood estimators (TMLEs)
(Porter, Gruber, Van Der Laan, & Sekhon, 2011), which were double robust semi-parametric
estimators, among many others (Kang & Schafer, 2007).
Machine-learning based approaches offer much flexibility in terms of estimating ITE.
However, the lack of counterfactuals for ITE estimation poses a difficulty for applying any
supervised learning technique directly. The majority work in this area used tree-based
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methods to estimate the counterfactuals first and then made inferences about heterogeneous
treatment effect on subgroup level or ITE on individual level. For example, Jennifer Hill
discussed the potential of Bayesian additive regression trees (BART), which naturally
learned heterogeneous treatment effects without pre-specification (Hill, 2011). Athey and
Imben introduced an algorithm based on regression trees, where they first used a subsample
to construct a partition of the population, and then estimated the causal effects within each
partition to identify the heterogeneity (Athey & Imbens, 2016). Lu et al. compared several
tree-based methods for estimating ITE and concluded that counterfactual synthetic random
forest achieved best performance by constructing separate forests for each treatment (Lu,
Sadiq, Feaster, & Ishwaran, 2018). Wager and Athey developed a nonparametric causal
forest under the counterfactual framework, which extended previous algorithms into both the
classification and regression scenarios (Wager & Athey, 2018). In addition, they proved the
consistency and asymptotic properties for their estimators.
Given the increasing popularity of deep learning algorithms, several group of
researchers has started to tackle the problem of ITE estimation using neural networks.
Johansson et al. borrowed ideas from learning representations and domain adaption,
proposing to first learn a representation of the features/confounders and then the function that
maps the treatment and the learned representation to the outcome domain. Besides ensuring
low-error prediction of the factuals and counterfactuals, they additionally emphasized to
balance the distribution of features of the treatment populations through enforcing similarity
between learned representations for treatment arms (Johansson, Shalit, & Sontag, 2016).
Shalit et al. adopted the same idea by proposing a network structure that had a shared
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representation layer before splitting into two arms to estimate the outcomes for two treatment
respectively. They incorporated the integral probability metric (IPM) measure of distance to
ensure the similarity between two treatment groups over the shared representation layer
(Shalit, Johansson, & Sontag, 2017). Alaa et al. formulized ITE estimation as a multi-task
learning problem and unified propensity score approach and deep neural networks, which
they named as the deep counterfactual networks with propensity-dropout (DCN-PD) (A. M.
Alaa, Weisz, & van der Schaar, 2017). This network consisted of two sub-networks, one
multitask network with a few shared layers before splitting into two feed-forward arms for
the potential outcomes, and a feed-forward network to learn propensity scores. Propensity
scores were used to determine the dropout probability. The dropout probability was higher
for subject whose propensity score was around 0.5, indicating ambiguous treatment
assignment. Alaa and van der Schaar adopted a nonparametric Bayesian framework in which
they model the potential outcomes as the outputs of a function in a vector-valued reproducing
kernel Hilbert space (vvRKHS)(A. M. Alaa & van der Schaar, 2017). This multitask
Gaussian process for ITE inferences enable the estimation of credible intervals, which came
very handy in terms of precision medicine. Recently, Yoon et al. introduced the novel
framework, termed generative adversarial nets for individualized treatment effects
(GANITE) (Yoon, Jordon, & van der Schaar, 2018b), where they implemented two separate
GAN blocks for generating potential outcomes and estimating ITE. This was the first attempt
to incorporate GAN into the area of ITE estimation, which served as a strong motivation for
this dissertation work.
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1.5.5 Causal Discovery
All the previous discussion for causal inference focuses on determining the treatment
effect assuming the causal DAG is known, which is barely the case in reality. Therefore,
another problem that has attracted much attention is to determine the causal structure, termed
‘causal discovery’(Spirtes & Zhang, 2016). Given the need to determine causal structure
from observational data, several groups of researchers have proposed constraint-based search
for causal structures (Spirtes & Zhang, 2016). These type of algorithms rely on checking
conditional independence in the population and background knowledge, which output
graphical objects representing a Markov equivalence class (Spirtes & Zhang, 2016). Thus,
this type of algorithms do not output unique patterns and could not check all possible DAGs
(Spirtes & Glymour, 1991; Spirtes et al., 2000). Over the past few years, the general-purpose
Boolean Satisfiability Solver (SAT) was proposed as a constrained optimization technique
used for causal discovery, but such algorithm does not scale well when the number of
variables involved in a causal structure is large due to the difficulty in optimization
(Hyttinen, Hoyer, Eberhardt, & Jarvisalo, 2013; Spirtes & Zhang, 2016; Triantafillou &
Tsamardinos, 2015).
Another fundamental problem that directly ties to causal discovery is how to
determine the causation direction between two variables based on observational data (Spirtes
& Zhang, 2016). The key to this problem is to capture the information asymmetry in the data.
The first class of methods is based on SEMs involving X and Y. Such SEMs can be
formulized using the following mathematical equations:
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𝑌 = 𝑓(𝑋, 𝜀 ; 𝛳 )
𝑋 = 𝑔(𝑌, 𝜀 ; 𝛳 )
Here ε and ε are error terms independent of X and Y respectively. 𝑓 and 𝑔 denote the
functions describing how one variable is generated from another, which belong to a class of
properly constrained class. 𝛳 and 𝛳 are parameters involved in 𝑓 and 𝑔. The above two
SEMs are fit using the data and the direction in which the estimated error term is independent
of the hypothetical cause is considered the plausible direction based on the observed data
(Spirtes & Zhang, 2016). However, this type of SEM based methods suffer from the
identifiability problem, which depends on if the causal asymmetry can be reflected in the
observed data. For example, when 𝑓 and 𝑔 are linear functions and the error terms is
normally distributed, the causal direction is undefinable. Therefore, constraints are needed
for the mapping functions 𝑓 and 𝑔 such that the independence condition holds only for one
direction when it comes to SEM-based methods (Spirtes & Zhang, 2016).
When SEMs are too restrictive, nonlinear additive noise model (ANM) can be used to
introduce the nonlinear generating mechanism (Hoyer, Janzing, Mooij, Peters, & Schölkopf,
2009; Peters, Janzing, & Schölkopf, 2010). Mathematically, ANM is a class of model
satisfying the following formulation:
𝑌 = 𝑓(𝑋; 𝛳 ) + 𝜀
The ANM is a special case of post-nonlinear causal models (PNL) (K. Zhang & Hyvärinen,
2009a, 2009b), which applies the non-linear transformation twice:
𝑌 = 𝑓 (𝑓 (𝑋; 𝛳 ) + 𝜀 )
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Determination of plausible causal direction for ANMs and PNLs also relies on fitting the
models in both the forward and backward fashions and test for independence between the
estimated error terms and hypothetical cause.
Despite the great potential of GANs and the remarkable similarity between the
formulation of GAN’s generator and SEMs, this deep learning approach has not been
introduced into the field of causal discovery until recently. Lopez-Paz and Oquab introduced
the classifier two-sample test (C2ST) to determine if two samples are drawn from the same
distribution, which could be used as a metric to monitor the convergence of GANs (LopezPaz & Oquab, 2016). They discussed the novel application of this test for causal discovery.
However, their results were more of a proof-of-concept realization without formally defining
a test statistic and assessing the power and errors.
2. Public Health Significance
Patient heterogeneity has caused many uncertainties in medical research and clinical
practice. For example, individuals tend to have various environmental exposure, genomic
profiles and health status, leading to differential risks for diseases; although same type of
targeted therapy is administrated, people with same clinical conditions may respond
systematically different due to their own unique immune background (Reuben et al., 2017).
Therefore, personalized medicine has been proposed as a remedy to the problem of
heterogeneity, which uses patients’ specific information to predict risks, plan treatments or
make a prognosis (https://www.cancer.gov/publications/dictionaries/cancerterms/def/personalized-medicine).
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However, the path to personalized medicine has not been straightforward (Hamburg
& Collins, 2010). Technology advancement enables the collection of massive data for each
individual such as genomic profile or biomedical imaging, but how to tease out useful
information and guide clinical practice remains a major problem. As challenging as it may
sound, we are making tremendous progress with the help of deep learning algorithms.
My dissertation will help to address the problems arising in personalized medicine
from three different aspects. First, I will develop a novel framework to estimate
individualized treatment effects (ITE), which quantifies the variations in response to the
same treatment among patients with heterogeneous profiles. The ITE estimation will have the
potential to replace the one-size-fits-all average treatment effects (ATE) commonly used in
clinical practice and provide patient-specific treatment guidance. Second, I will develop a
statistical test to determine pairwise causation between two sets of continuous variables.
Despite of the massive data available, the primary methods to determine causation clinically
are still through randomized controlled experiments and animal studies, which are highly
inefficient or sometimes even infeasible. With this new statistical test, we will be able to
draw causal conclusions from observational data instead of experimental data alone, which
will be beneficial in terms of understanding underlying disease mechanisms. Last but not
least, I will apply the previously developed methods on real-life datasets to demonstrate their
usage, which hopefully will help to empower the clinicians and the patients to make
informed treatment plans.

20

3. Specific Aims
Personalized approaches have shown great potentials to transform modern medicine.
As challenging as it may sound, we are making tremendous progress with the help of data
sciences and machine learning. Two fundamental tasks in data sciences are prediction and
inference. In this dissertation, I proposed to address these two tasks using deep learning
approaches in the setting of personalized medicine. Aim I focused on the prediction part,
which was aimed to develop a method to estimate individualized treatment effects in contrast
to population-based effect estimates. Aim II emphasized on the inference part, involving
determining the pairwise causations from observational data when randomized trails are not
feasible. Aim III demonstrated how to incorporate previously developed methods into
biomedical analysis by leveraging various types of data including clinical factors, gene
expression and images that characterize patients’ individualized profiles. In addition, I also
addressed the ‘black-box’ criticism around deep learning application by creating an
interpretable diagnosis system based on images for Alzheimer’s disease.
Aim 1: To develop a generative adversarial network (GAN)-based approach to
estimate individualized treatment effects. In contrary to the one-size-fits-all populationlevel effect sizes, GAN was used to infer the unseen, individual counterfactuals based on
factual outcomes, which later was used to obtain the personalized treatment effects. This
approach was compared with other state-of-art methods through simulations.
Aim 2: To develop a novel statistical test combined with GANs to determine
pairwise causation between two sets of continuous variables. Given the strong
resemblance among the assumptions of GAN, the additive noise models (ANMs) and the
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structural equation models (SEMs) for causal inferences, a novel framework was established
by replacing the conventional non-linear functions in ANMs with neural networks. Three
different scenarios, when there is neither association nor causation, when there is association
only, and when both association and causation exist were explored.
Aim 3: To demonstrate how to incorporate previously developed methods into
biomedical analysis by leveraging various types of data including clinical factors, gene
expression and images. Patients with lung cancer from The Cancer Genome Atlas Program
(TCGA) with high-dimensional complex features were included in the first analysis. I
quantified the variations of days to death in response to the cancer treatment among patients
with heterogeneous clinical and genetic profiles. My second analysis provided an end-to-end
framework for Alzheimer’s disease from automatic diagnosis of medical images by artificial
intelligence to results interpretation including feature selection and causal discovery.
METHODS
1. Individualized Treatment Effect (ITE) Estimation
1.1 Problem Formulation
The problem of individualized treatment effect (ITE) is best defined under the
counterfactual framework introduced by Hernan and Rubin (Hernán MA, 2019). Let capital
letters denote random variables and small letters denote the realization of the random
variables. 𝑋 stands for feature vectors. 𝑇 stands for an action/treatment/intervention. In the
case of binary treatment, T takes the value of 0 or 1. Let 𝑌 be the outcome. Mathematically,
the problem of ITE can be defined as
𝜏(𝑥) = 𝐸(𝑌

|𝑥) − 𝐸(𝑌

|𝑥) = 𝐸(𝑌
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−𝑌

|𝑥)

(1)

This is the expected difference between the outcome when 𝑇 takes the value of 1 and the
outcome when 𝑇 is 0 for an individual whose feature vector equals to 𝑥 (Shalit et al., 2017).
The key here is that only one outcome, either 𝑌

or 𝑌

, can be observed in reality,

depending which treatment the patient actually receives. Therefore, the outcome that is
observed is called the factual outcome, whereas the outcome that is not observed is defined
as the counterfactual outcome.
Consistency, exchangeability and positivity are the necessary assumptions for valid
ITE estimation using observational data to mimic a randomized controlled trial (Hernán MA,
2019). Consistency refers to a consistent definition of treatment; the values of treatment
under comparison correspond to well-defined interventions that, in turn, correspond to the
versions of treatment in the data (Hernán MA, 2019). Exchangeability is perhaps the most
important assumption for observation causal inference. Exchangeability indicates conditional
independence 𝑌

⫫ 𝑇|𝑋, which is equivalent to no residual confounding in epidemiology.

This is a very strong assumption because you can never guarantee the data capture every
feature that is related to both the treatment and the outcome. Positivity requires that the
conditional probability of receiving every value of the treatment is greater than 0 (0 <
𝑃(𝑇 = 𝑡|𝑥) < 1). Exchangeability and positivity are also called strong ignorability in some
literature (A. M. Alaa et al., 2017; Shalit et al., 2017).
1.2 Model Description
Yoon et al. proposed to use the generative adversarial networks for data imputation,
which they termed ‘GAIN’ (Yoon, Jordon, & van der Schaar, 2018a). In comparison to the
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standard conditional GAN, GAIN’s generator was trained to fill in the missing values,
whereas the discriminator was aimed to distinguish the observed data and the imputed data.
In addition to the discriminator and the generator, the authors added a ‘hint’ mechanism
where they provided the discriminator with some extra information depending on the missing
patterns. They showed that their algorithms outperformed the state-of-art methods on many
datasets.
ITE estimation is essentially a data imputation problem. Counterfactuals will need to
be estimated/imputed before taking the difference of outcomes to get ITE. Therefore, I
proposed to address the problem of ITE estimation by building on and adapting the structure
of GAIN, to create a framework called Counter-Factual Generative Adversarial Imputation
Networks (CFGAIN). Specifically, CFGAIN made two main changes to the structure of
GAIN. First, instead of merging X and Y together as the target data vector that needed to be
filled with imputed values, I borrowed the structure of conditional GANs and treat X as
conditions to both the discriminator and generator. Second, in the case of high-dimensional
covariates with complex structure that affect ITE distribution (e.g. gene expression profiles),
an encoding block was added to perform automatic data reduction, which took X as the input
and extracted relevant features V from the hidden space. The features were used as
conditions to both the generator and discriminator instead of directly using X. Figure 5
illustrates the design of the proposed network CFGAIN in the case of a binary treatment.
We start with the input dataset to CFGAIN as 𝐷 = {𝒕𝒊 , 𝒙𝒊 , 𝒚𝒊 }

. Here 𝒕𝒊 denotes the

treatment vector for subject i, which is in a m-dimensional space, corresponding to m types
of treatment. The nth element of 𝒕𝒊 (i.e. 𝒕𝒊 ) takes the value 1 if subject i receives the nth
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treatment. Otherwise, 𝒕𝒊 = 0. 𝒚𝒊 is the observed outcome vector with the length of m. The nth
element of 𝒚𝒊 (i.e. 𝒚𝒊 ) takes the value of the observed factual outcome if subject i receives
the nth treatment. Otherwise, 𝒚𝒊 is replaced with a random noise sampled from the uniform
distribution [0,1).
𝒙𝒊 is the set of realization values of the covariates for subject i. If {𝒙𝒊 }

is high-

dimensional with complex structure such as medical images, it will first go through a feature
extractor, consisting of a few fully-connected layers or convolutional layers to tease out
useful features {𝒗𝒊 }

for the generator G and discriminator D.

The generator G takes {𝒕𝒊 , 𝒗𝒊 , 𝒚𝒊 }

as input and outputs {𝒚 }

, which are the

generated outcome vectors, with both the factual and counterfactual outcomes replaced by
generated values. I will use {𝒚 }

to denote the imputed outcome vectors, where only the

counterfactual outcomes are replaced with the values generated by G.
The hint mechanism H is self-defined. Depending on the value of 𝒕𝒊 , 𝒉𝒊 can be
sampled from the distribution H|T=𝒕𝒊 . This hint mechanism provides the discriminator D
with some information about the treatment assignment, which has been shown to be
necessary for G to reproduce a unique optimal distribution with respect to D.
The discriminator D takes {𝒉𝒊 , 𝒗𝒊 , 𝒚 }

as input and outputs vectors of size m, with

each element indicating the probability of the corresponding element in 𝒚 being a factual
outcome.
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1.3 Optimization
Similar to standard GAN, the optimization is conducted in an adversarial fashion. The
discriminator D is trained to maximize the probability to correctly identify factual outcomes,
whereas the discriminator G is trained to minimize such probability. The loss functions for
the D and G can be written as
𝐿 = −𝐸[𝑇 𝑙𝑜𝑔(𝐷 𝐻, 𝑉, 𝑌 ) + (1 − 𝑇) 𝑙𝑜𝑔(1 − 𝐷 𝐻, 𝑉, 𝑌 )]
𝐿 = 𝐸 𝑇 𝑙𝑜𝑔 𝐷 𝐻, 𝑉, 𝑌

The extra 𝐿

+ (1 − 𝑇) 𝑙𝑜𝑔 1 − 𝐷 𝐻, 𝑉, 𝑌

+ 𝛼𝐿

(2)
(3)

term respects the fact that the corresponding elements in the generated

outcome vectors {𝒚 }

should be as close as the factual outcomes. Let J i be the number of

factual outcomes for subject i:
𝐿

=∑

∑

(𝑦 − 𝑦 )

(4)

The vanilla version of GAN is notorious for its difficulty in training. GAN is defined
as a minmax game which requires to update the parameters of D and G in the same training
process. G may stop learning if D is too well trained. It is difficult to find ideal sets of hyperparameters to balance between D and G. In addition, vanilla GAN also suffers from nonconvergence, mode collapse, diminished gradient and lack of quantitative measures
indicating the distance between the generated distribution and the true distribution (Hui,
2018). Therefore, I used WGAN to replace GAN whenever it was too difficult to find good
hyper-parameters.
WGAN proposes a new cost function, which relies on the Wasserstein distance or
earth-mover distance (EM distance) (Arjovsky et al., 2017). EM distance is the smallest
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distance needed to convert one distribution into another. The loss functions for WGAN can
be written as
(5)

𝐿 = −𝐸[𝑇 𝐷 𝐻, 𝑉, 𝑌 + (1 − 𝑇) (1 − 𝐷 𝐻, 𝑉, 𝑌 )]
𝐿 = 𝐸 𝑇 𝐷 𝐻, 𝑉, 𝑌 + (1 − 𝑇)

1 − 𝐷 𝐻, 𝑉, 𝑌

+ 𝛼𝐿

(6)

Here the loss of D is an estimation of the Wasserstein distance, which is a quantitative
measure related to the convergence of WGAN. In addition, WGAN applies a clipping to the
weights of D to ensure Lipschitz constraint (Arjovsky et al., 2017).
(7)

𝑤 ← 𝑐𝑙𝑖𝑝(𝑤, −0.01,0.01)

As proposed by the original study, RMSProp is used as the optimizer for WGAN training.
1.4 Simulation Experiments
Statistical simulation was conducted to evaluate the performance of the proposed
algorithm, in comparison with linear regression, propensity score method, k nearest neighbor
regression and random forest, when the treatment is binary. Synthetic data was generated for
two scenarios. Scenario I corresponds to the simple case when the covariate that affects ITE
has only a single dimension:
1) Draw the covariate vector X from the standard normal distribution for 10,000
individuals;
2) Define a non-linearity function 𝑓(𝑥) =

(

)

;

3) Draw 𝒚𝟎 = 0.3 + 𝒏𝟎 , where 𝒏𝟎 is the randomly sample noise vector from normal
distribution 𝑁(0, 𝑆𝐷 = 0.1);
4) Draw 𝒚𝟏 = 0.3 + 𝑓(𝑿) + 𝒏𝟏 , where 𝒏𝟏 is the randomly sample noise vector from
normal distribution 𝑁(0, 𝑆𝐷 = 0.1);
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5) Treatment 𝑡 is drawn from a bernoulli distribution with 𝑝 = 0.5 for each subject.
Scenario II corresponds to the case when the ITE distribution is affected by some
high-dimensional feature with complex structure:
1) Generate 𝑋 as an image of 28x28 pixels, containing a circle with random radium 𝑅
and random center 𝑄 (R. Chen & Liu, 2018).
a) First determine the radius 𝑅 by sample integers randomly from [0.14).
b) To determine the origin 𝑄 , draw the coordinates by randomly sample from [0,28)
for both coordinates.
c) For pixel values inside the circle, assign a value of 180. Otherwise, let the pixel
values be 0.
2) Draw 𝒚𝒊𝟎 from the standard normal distributions for 10,000 subjects.
3) Draw 𝒚𝒊𝟏 from 𝑁(𝑅 , 𝑆𝐷 = 1) for all 10,000 subjects.
4) Treatment 𝑡 is drawn from a Bernoulli distribution with 𝑝 = 0.5 for each subject.
The evaluation metric for ITE was the mean squared error (MSE). Average treatment effect
(ATE), average treatment effect on the treated (ATT) and average treatment effect on the
control (ATC) will also be reported as a sanity check. Below are the mathematical definitions
for the evaluation metrics:
𝑀𝑆𝐸 =

∑

(𝑦
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−𝑦 )

(8)

2. Adversarial Causal Test (ACT)
2.1 Problem Formulation
As discussed before, causal discovery is a crucial problem that need to be addressed
before any valid treatment effect estimation. Causal discovery focuses on determining the
causal structure among several variables. The most fundamental and simple problem is to
determine if two variables X and Y have causal relation and if so, what is the direction for
that causal relation. Previous methods tend to emphasize the latter part of the problem while
assuming the first part is true (Hoyer et al., 2009; Peters et al., 2010). Therefore, I propose an
end-to-end algorithm to test for causations and determine the direction for the causation,
which is an extension to the work by Lopez-Paz and Qquab on causal discovery using
conditional GANs (Lopez-Paz & Oquab, 2016). Due to the identifiability issues associated
with discrete variables (Spirtes & Zhang, 2016), I will focus on the causation between two
continuous sets of variables.
2.2 Model Description
2.2.1 Classifier Two-Sample Test (C2ST)
The classifier two-sample test was introduced by Lopez-Paz and Qquab.(Lopez-Paz
& Oquab, 2016) Assuming there are two samples, 𝑆 ~𝑃 and 𝑆 ~𝑄 . The null hypothesis
of C2ST is 𝑃 = 𝑄, whereas the alternative hypothesis is 𝑃 ≠ 𝑄. C2ST aims to determine if
we could reject the null hypothesis through observed samples:
𝑆 ≔ {𝑥 , … , 𝑥 }~𝑃 (𝑋) and 𝑆 ≔ {𝑦 , … , 𝑦 }~𝑄 (𝑌)
The test will be conducted in the following steps:
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1) Construct the dataset 𝐷 = {(𝑥 , 0)}

∪ {𝑦 , 0)}

≔ {𝑧 , 0)}

;

2) Shuffle the dataset 𝐷 first and then split the data into a training set 𝐷
𝐷

and a test set

;

3) Train a binary classifier on 𝐷

;

4) Test the classier on the test set and get the classification accuracy 𝑡̂, which is the test
statistic following 𝑁( ,

) under the null using the central limit theorem:
𝑡̂ =

∑(

𝐼[𝐼 𝑓(𝑧 ) >

, )∈

(9)

=𝑙]

2.2.2 Adversarial Causal Test (ACT)
Figure 6 illustrates the procedure for conducting the ACTs. Specifically, the
following steps should be taken:
1) Train a CGAN from X to Y 𝐷
2) Apply the C2ST test on
accuracy 𝑡

⇾

=

𝑥 , 𝑔 (𝑥 , 𝑧 )
and {(𝑥 , 𝑦 )}

𝑥 , 𝑔 (𝑥 , 𝑧 )

∑

=

⇾

𝑤

3) Train a CGAN from X to Y 𝐷

⇾

= {(𝑔 (𝑦 , 𝑧 ), 𝑦 )}

4) Apply the C2ST test on {(𝑔 (𝑦 , 𝑧 ), 𝑦 )}
accuracy 𝑡

⇾

∑

=

(

)

-

∑

(

⇾

and {(𝑥 , 𝑦 )}

to get the classification

𝑣

5) Calculate the ACT test statistic 𝑇 =
2

to get the classification

)(

⇾

)

( ⇾

⇾

𝝈

)

, where 𝝈 =

, 𝑝 = and T follows a Chi-square distribution with

1 degree of freedom under the null hypothesis of no causation.
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6) If the null hypothesis is rejected, the causal direction could be determined by comparing
𝑡

⇾

and 𝑡

⇾

with 0.5. The one closer to 0.5 corresponds to the correct direction.

2.3 Optimization
Similar to section 1.4, the training process of CGAN involves 𝐺 and 𝐷 playing the
following two-player minmax game with mini batch size of M:
𝐿𝑜𝑠𝑠 = −𝑉(𝐷, 𝐺) + 𝐿

( 10 )

𝐿𝑜𝑠𝑠 = 𝑉(𝐷, 𝐺) + 𝐿

( 11 )

Besides the standard gradient penalty for the discriminator, an extra feature mapping term
will be added to the loss function of the generator to avoid the over training of the
discriminator, which takes in the output from the last hidden layer and calculates the mean
square error between the real data 𝑂 (𝒙𝒊 |𝒚𝒊 ) and the fake data 𝑂 (𝐺(𝒛 |𝒚𝒊 )) generated by the
generator for a mini batch of size M:
𝑉(𝐷, 𝐺) = 𝐸[𝐷(𝑋|𝑌)] − 𝐸[𝐷 𝐺(𝑍|𝑌) ]
𝐿

= 𝜆 𝐸[ |𝛻𝑿 𝐷(𝑿)|

𝐿

=

∑

−1 ]

( 𝑂 (𝒙𝒊 |𝒚𝒊 ) − 𝑂 (𝐺(𝒛 |𝒚𝒊 )))

( 12 )
( 13 )
( 14 )

The algorithm updates the discriminator and the generator iteratively using the stochastic
optimizer RMSprop until convergence (Tieleman & Hinton, 2012).
2.4 Simulation Experiments
Statistical stimulation was conducted using synthetic data to evaluate the type I error
and power of the proposed test. Three different scenarios were explored. Type I error is
defined the probability of significant results at a pre-specified significance level when the
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null hypothesis of no causation should not be rejected. Power is defined as the probability of
successfully rejecting the null hypothesis of no causation when there is causation. I also
reported the power of correctly identifying the causation direction.
Scenario I corresponds to the case where there is no association and no causation.
Data will be generated in the following steps:
1) Sample X from the standard normal distribution, which is a vector with length
10,000;
2) Sample Y from the standard normal distribution, which is a vector with length
10,000;
3) Test the independence between X and Y using the Hilbert Schmidt independence
criterion (dHSIC);(Gretton et al., 2008; Pfister, Bühlmann, Schölkopf, & Peters,
2018)
4) If the p-value from dHSIC test is significant under the pre-specified significance level
0.05, discard X and Y; otherwise, randomly sample realizations from X and Y as a
dataset, at sample size of 500, 1000, 2000;
5) Repeat the above procedure until accumulate 1000 datasets, each containing X and Y;
6) Repeat the above procedure for a significance level at 0.01.
Scenario II corresponds to the case where X and Y are associated but no causation.
Data was generated in the following steps:
1) Sample X from the standard normal distribution, which is a vector with length
10,000;
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2) Sample Y from the standard normal distribution, which is a vector with length
10,000;
3) Test the independence between X and Y using the Hilbert Schmidt independence
criterion (dHSIC) (Gretton et al., 2008; Pfister et al., 2018);
4) If the p-value from dHSIC test is significant under the pre-specified significance level
0.05, randomly sample realizations from X and Y as a dataset, at sample size of 500,
1000, 2000; otherwise, discard X and Y.
5) Repeat the above procedure until accumulate 1000 datasets, each containing X and Y;
6) Repeat the above procedure for a significance level at 0.01.
Scenario III corresponds to the case where X and Y have causal relations. Data was
generated in the following steps:
1) Randomly sample X from the standard normal distribution with a sample size of
100,000;
2) Generate the random noise N of the same dimension as X from the normal
distribution with mean=0 and SD=0.1;
3) Generate Y by non-linear mappings 𝑓 from X and N:𝑦 = 𝑓(𝑥 ) + 𝑛
4) Randomly sample X and Y to create 100 datasets at sample size of 200, 500, 1000,
2000, 5000, so there are a total of 500 datasets for each nonlinear function 𝑓.
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3. Application Studies
3.1 ITE Estimation for TCGA
3.1.1 Simulation using Gene Expression for Pancreatic Cancer
Contrast to previous two simulation settings where all data was purely generated, I
borrowed the gene expression profiles from TCGA pancreatic cancer study as covariates, and
only synthesize data reflecting treatment effects:
1)

Randomly select 1000 genes from whole gene expression profile and calculate

the mean expression levels for the 1000 genes µ𝒊𝟎 . Draw 𝒚𝒊𝟎 from exp(𝜆 = 1)+ µ𝒊𝟎 /𝟏𝟎.
2)

Randomly select another 1000 genes from the whole expression profile. Input

the selected gene values into an autoencoder, which learns the hidden representations of the
genes L.
3)

Input L to a neural network with 1 hidden layer of 256 neurons and the

sigmoid activation to generate ITEs. The neural network is initialized with random weights
and bias but does not go through any training process.
4)

Draw 𝒚𝒊𝟏 from 𝑦 = 𝑦 + 𝐼𝑇𝐸 + 𝑛𝑜𝑟𝑚𝑎𝑙(0,0.05).

3.1.2 ITE Estimation for Lung Cancer
Patient heterogeneity has caused many uncertainties in medical research and clinical
practice. In this project, we applied CFGAIN to quantify variation in days to death, in
response to the same treatments among patients with heterogeneous genetic profiles. Based
the estimation, best treatment strategy could be recommended to future patients, taking
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individual genetic profile into consideration. The ITE estimation will have the potential to
replace the one-size-fits-all average treatment effects (ATE) commonly used in clinical
practice and provide patient-specific treatment guidance.
Lung cancer has been the leading cause of cancer-related deaths in the US (Barta,
Powell, & Wisnivesky, 2019). Although both the incidence rates have declined in the US, 5year survival rate for lung cancer is around 20% and among the lowest for all cancer
("Cancer Facts & Figures 2019 - American Cancer Society," 2019). Lung cancer can be
grouped into two major types depending on the aetiology: small-cell lung cancer (SCLC),
and non-small-cell lung cancer (NSCLC), accounting for 80% of lung cancers (R.,
2013). Only 16% of lung cancer cases diagnosed are at localized stages ("Cancer Facts &
Figures 2019 - American Cancer Society," 2019). Advanced-stage lung cancer is usually
treated with chemotherapy, radiation, a combination of both or immunotherapy.
Differential response to treatment for lung cancer has been reported extensively in
literature, which can be attributed to heterogeneous genetic profiles. For example, it has been
shown that mutations in HER1/EGFR are associated with positive response of targeted
therapy and poor prognosis and resistance to chemotherapy (Cooke, Reeves, Lannigan, &
Stanton, 2001). A few studies identified CCND1 overexpression as a marker associated with
poor prognosis (Esposito et al., 2005; Ikehara et al., 2003; Jin et al., 2001). In addition, a few
groups reported that some mRNAs and microRNAs (miRNAs) were significantly associated
with prognosis in NSCLC patients (Hu et al., 2010; Raponi et al., 2009). The fact that genetic
markers are important for the differential prognosis makes lung cancer a good candidate for
us to apply CFGAIN.
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TCGA (https://www.cancer.gov/about-nci/organization/ccg/research/structuralgenomics/tcga) is a large-scale cancer genomics program, supported by the National Cancer
Institute (NCI) and the National Human Genome Research Institute. It was initiated in 2006
and included extensive genomic, epigenetic, transcriptomic and proteomic data for over 33
cancer types. The TCGA lung cancer data used in this study included samples from three
projects: TCGA-LUSC, TCGA-LUAD and TCGA-MESO. After merging clinical
information, treatment strategies and days to death, a sample of 186 subjects with complete
data was used for this analysis. Their expression profiles of 60,483 genes were extracted to
be used as covariates to estimate ITE. Among the study subjects, 80 subjects had
chemotherapy only and 39 subjects had radiation therapy only, whereas 67 subjects had
combinational therapy of both chemotherapy and radiation. Demographic and clinical factors
that were also used for ITE estimation included age at diagnosis, gender, race, ethnicity,
diagnosis, tumor stage, tumor morphology, tumor origin and which project the subject
belonged to.
Over 60,000 gene expression values were encoded into a vector of 128 latent factors.
To increase the efficiency of information processing by CFGAIN, gene expression values
were arranged into a 2X2 matrix in size of 236x238 with padding 0s in the end.
Convolutional filters were used in the auto-encoder. To ensure fair comparisons, the 128
latent factors were used to summarize information from gene expression profiles for all
methods. Results from linear regression, propensity score regression, K nearest neighbors
and random forest were compared with results from CFGAIN. After getting the complete
outcome vectors, ITE was calculated for each subject. The treatment therapy corresponding
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to the longest survival days was chosen as the recommended treatment. Since ITE was
defined as the difference between two treatment arms, so three pairwise comparison was
conducted to calculate ATE, ATT and ATC.
One fundamental difficulty for applying machine-learning based ITE estimation to
real data is the lack of counterfactual outcomes to validate the results. Researchers have been
using simulated data, where they manually define the data generating process so that they
know both the factual outcomes and the counterfactuals, to demonstrate the superiority of
their methods (Yoon et al., 2018b; W. Zhang, Le, Liu, Zhou, & Li, 2017). However,
simulated data are generally not so reflective of real-life datasets. Since match-learning based
estimation are data-driven approaches, it has been established that each dataset has its own
suitable method. Therefore, it is important to apply validation measures to compare the
performance of various methods.
Plug-in validation was applied to the TCGA lung cancer dataset, which obtained a
plug-in precision of estimating heterogeneous effects (PEHE) estimate (Rolling & Yang,
2014; Schuler, Jung, Tibshirani, Hastie, & Shah, 2017). PEHE quantified a model’s ability to
capture the heterogeneous causal effect of a treatment among individuals (Hill, 2011). An
empirical measure of PEHE is defined as

(𝑇(𝑋 ) − 𝑌

( )

−𝑌

( )

) , where 𝑇(𝑥) =

𝐸 [𝑌 ( ) − 𝑌 ( ) |𝑋 = 𝑥] and 𝜃 is the parameter space, with nuisance parameters {𝜇 , 𝜇 , … }.
For each individual, the counterfactuals, either 𝑌

( )

or 𝑌

( )

is unknown, it is impossible to

calculate the empirical PEHE. The plug-in model 𝜃 = {𝜇 , 𝜇 , … } can be estimated from the
observed data by fitting supervised regression models to the subsets of data {(𝑋 , 𝑌 )|𝑇 = 0}
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and {(𝑋 , 𝑌 )|𝑇 = 1}. Let us define 𝑇(𝑥) = 𝜇 (𝑥) − 𝜇 (𝑥). The plug-in validation PEHE
estimator can be estimated as 𝛴 𝑇(𝑋 ) − 𝑇(𝑋 ) . The supervised regression models I
used here was gradient boosting regression (i.e. XGBoost Regresssion) (T. Chen, He,
Benesty, Khotilovich, & Tang, 2015).
To further understand which latent factors and genes played important roles for ITE,
lasso regression with 5-fold cross validation was performed by regressing ITE estimates
against latent factors. After important features were selected, multiple linear regression was
performed on ITE vs. selected features and R2 was reported. To map latent factors to genes,
Spearman correlation was calculated for each of the genes and each of the latent factors
selected from Lasso regression.
3.2 Causal Discovery for ADNI
Alzheimer’s disease (AD) that causes progressive brain atrophy and memory loss is a
progressive, irreversible degenerative disease of the brain and is the most common
neurodegenerative disease in the world (Xiaonan Liu et al., 2018; Xin Liu et al., 2018;
Struyfs et al., 2015; Zhuang, Zheng, Gu, Shen, & Ji, 2017). An estimation of 5.4 million
Americans and more than 30 million people in the world are affected. It is estimated that
these numbers will be tripled by 2050. AD is the sixth leading cause of death in the USA
(Association, 2016; Leandrou, Petroudi, Kyriacou, Reyes-Aldasoro, & Pattichis, 2018)
Diagnosis and prediction of AD via clinical and psychometric assessment is
challenging (Leandrou et al., 2018). It is difficult for AD patients to be early and accurately
identified through clinical dementia rating and cognitive tests. A final diagnosis of AD can
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only be confirmed by histological examination at postmortem biopsy. Although histological
examination of the brain for the living patients is infeasible, individually varying brain
structure, function and the pathological effects can be measured by images. Therefore,
imaging plays an important role in improving diagnosis and prediction of AD. According to
the recommendation by the National Institute of Neurologic, Communicative Disorders and
Stroke–AD and Related Disorders Association (NINCDS-ADRDA) Work Group, the clinical
classification of AD should explore the image markers: magnetic resonance imaging (MRI),
diffusion tensor imaging (DTI), positron emission tomography (PET), amyloid-PET, tauPET and abnormal neuronal cerebrospinal fluid (CSF) markers (tau and/or Aβ) (Dubois et
al., 2007; Leandrou et al., 2018).
As the size of the imaging datasets increases, manual analysis of imaging data is
tedious and time consuming. Computer-aided diagnosis (CAD) of AD that combines
computational models and analytical tools for high dimensional imaging data analysis is
emerging as one of major tools for diagnosis and prediction of AD (Dimitriadis, Liparas, &
Initiative, 2018; Leandrou et al., 2018). The widely used machine learning methods in CAD
include discriminant analysis (DA), logistic regression (LR), random forest, neural networks,
and support vector machine (SVM) (Dimitriadis et al., 2018; Leandrou et al., 2018; Lorenzi
et al., 2017; Sarica, Cerasa, & Quattrone, 2017). Deep learning, a rapidly resurged subfield of
machine learning outperforms many classical ML approaches and is emerging as a major
analytic platform in machine learning (Esteva et al., 2019). Deep learning with massive
amount of computational power has achieved a great success in driverless cars, speech
recognition and imaging analysis (Waldrop, 2019), and demonstrated great potential for
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diagnosis and prediction power in tuberculosis (Heo et al., 2019), cancer (Esteva et al., 2017;
Ghatwary, Zolgharni, & Ye, 2019; Haenssle et al., 2018; Ladefoged et al., 2019), diabetic
retinopathy (Gulshan et al., 2016), chronic kidney disease (Ravizza et al., 2019), AD (Ding
et al., 2019; Hosseini-Asl, Keynton, & El-Baz, 2016; Ju, Hu, & Li, 2017; Payan & Montana,
2015; Sarraf & Tofighi, 2016; Spasov et al., 2019; Wada et al., 2019), and conversion from
mild cognitive impairment (MCI) to AD (Choi, Jin, & Initiative, 2018; Spasov et al., 2019).
There is a growing interest in application of deep learning to healthcare and medicine.
Despite its great success in computer vision, natural language processing, control,
decision-making, diagnosis and early detection of complex diseases, deep leaning is also
well known as a ‘black box’ due to its low interpretability to humans and still has a serious
opacity problem (Waldrop, 2019). Overcoming the limitation of the lack of transparency and
interpretation remains a great challenge for deep learning(Dubois et al., 2007). In this
project, I developed a novel framework that integrates deep leaning and causal inference for
image classification. The new framework consists of two stages: (1) convolutional neural
networks to classify AD status based on DTI and occlusion map to find image regions that
are most distinctive for disease status and (2) the state-of-the-art causal inference tools to
determine if the selected image regions are causal for AD.
Brain anatomy, structural connectivity and physical connection between brain regions
that are characterized through water molecular diffusing within white matter tracts can be
measured by DTI. The imaging signals provide intermediate endophenotypes. Genetic
variants will influence brain microstructure, function and disease development.
Understanding the role that genetics has in imaging and disease variation, is a key to getting
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inside into the causal chain of complex diseases (Bycroft et al., 2018; Elliott et al., 2018;
Jahanshad et al., 2013). Therefore, to further cover the genetic bases of brain structures and
function, and mechanism of AD, joint analysis of the genetic, brain images and AD was
carried out. I assessed both association and causal relationships among genetic variants, brain
regions and AD.
3.2.1

Materials
The DTI images used in this study are downloaded from the Alzheimer’s Disease

Neuroimaging Initiative (ADNI), sizes of each image was 91 × 109 × 91. ADNI is a
longitudinal multicenter study designed to develop clinical, imaging, genetic, and biomedical
biomarkers for the early detection and tracking of Alzheimer’s Disease (About ADNI.
Retrieved January 12th, 2019, from: http://adni.loni.usc.edu/about/#core-container.). DTI
images were recorded for every participant from different time-points in which they joined in
the research. In this study DTI images of 151 individuals from normal controls (NC) (100
images) and AD (51 images) groups were chosen from 4 different diagnostic time-points:
baseline, 6 months, 12 months, and 24 months.
3.2.2

Image Preprocessing
To make sure that all the images for this analysis are comparable, we registered all

the DTI image data for every subject every time point to the common template which could
be downloaded from the McConnell Brain Imaging
Center (http://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009). We utilized a
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strategy of combination of linear and nonlinear registration algorithm to map each individual
DTI data to the common template. During the linear image registration procedure, we first
mapped the image data to the common template to make sure all the image are within the
standard brain region by using FLIRT (FMRIB's Linear Image Registration Tool)
from FSL (FMRIB software library) image analysis suite (http://www.fmrib.ox.ac.uk/fsl/)
. Then we further applied non-linear registration algorithm which was implemented in
RNiftyReg to map the image details within the standard brain. The linear image registration
process helps us restrain each individual DTI image to a standard template and the nonlinear
image registration helps us to make sure the registered image maintain the structures details
as the original data.
To overcome the small sample size limitation of medical images, image augmentation
techniques were used (Aderghal, Boissenin, Benois-Pineau, Catheline, & Afdel, 2017). The
first technique we applied was Gaussian filters to blur the image to mimic the possible
variations in the original images. Filter size of 3 × 3, 5 × 5 and 7 × 7 were used with spread
parameters of 0.7, 0.7 and 0.6 respectively. The second augmentation technique we used was
translation, where we shifted the images by ±1 pixel in each dimension. This imitates the
possible variations in registration process where the images were aligned with the template.
Finally yet importantly, the images were flipped horizontally because some regions of the
brain (eg. the hippocampus) is symmetrical to enlarge our sample size. To balance the data,
we randomly duplicated some images from the under-sampled category. Data augmentation
and class balancing produced over 20 times more data than the original dataset.
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3.2.3 Genetic Data Preprocessing
We performed QC in both individual level and SNP level QC in the plink binary
format. For the individual level QC, the following steps were applied to the data.
1) Individuals with discordant gender information were removed from the data.
2) Individuals with missing rate >10% were removed from the data.
3) Individuals with heterozygosity rate more than 3 standard deviation from the mean were
excluded from the data.
4) Individuals with IBD > 0.185 were excluded from the data.
After the individual level QC was conducted, the following steps for SNP level QC
were further applied to the data.
1) SNPs with missing genotype rate > 10% were excluded from the data being analyzed.
2) SNPs with P - value for HWE test < 1E-6 were excluded from the data.
3) SNPs without polymorphism were removed from the data.
Then pre-imputation QC tool from MaCarthy groups was further applied to check the
data against 1000G reference data. The imputation of the genetic data were conduct under
the SHAPEIT+ IMPUTE2 framework in the internal computational clusters. The 1000G
reference data was used as the reference panel for imputation. After the imputation, the SNP
level QC steps were applied again to the data to produce the final genetic data for analysis.
Finally, a total of 1,589,061 common SNPs in 36480 genes genotyped in 151 individuals
were included in analysis.
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3.2.4 Architecture of Convolutional Neural Networks
We first developed a three-dimensional convolutional neural network (3D-CNN) by
modifying the classic AlexNet structure to classify AD and NC in this project (Krizhevsky et
al., 2012). The structure has 5 convolutional layers and 3 fully connected layers. Batch
normalization and dropout with a rate of 0.5 were used after the first two convolutional layers
to speed up training and deal with overfitting. The first two fully connected layers each had
128 neurons, which was different from the 2048 neurons in the original AlexNet. The input
to this network was 3D DTI images (109x91x91), whereas the output is a vector of predicted
probabilities for AD and NC. Five-fold cross-validation was used to develop the models.
3D whole brain images with 109×91×91 size were input into this CNN. Convolution
of an image with different filters can perform operations that capture various types of
features and directional information of DTI images, and preserve tract of DTI and the
relationship between pixels. 3D convolutional neural networks (3D-CNN) with 5
convolutional layers and 3 fully connected layers were used for AD prediction. 3 dimensional
(3D) filter was applied to the dataset and the filter moves in 3-direction (x, y, z) to calculate
the low level feature representations. Specifically, 3D filters were arranged as in Table 1.
Due to computational limitations, the two dimensional convolutional neural network
(2D-CNN) model VGG (Visual Geometry Group) that won the first and the second places in
the localization and classification tracks, respectively, in the ImageNet Challenge 2014 was
also explored and modified for image classification and prediction (Simonyan & Zisserman,
2014). To prevent over fitting and improve the image region recognition ability of the
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networks, Global Average Pooling (GAP) layer was used as a structure regularizer and
localizer in the model to identify the complete extent of the object and exactly which regions
of an image are being used for classification (B. Zhou, Khosla, Lapedriza, Oliva, & Torralba,
2016).
The model was trained in the Texas Advanced Computing Center (TACC) Maverick2
with NVIDIA GTX 1080 Ti GPUs.
3.2.5 Deep Feature Selection for DTI Images
Prediction difference analysis for visualizing the response of CNN to a specific input
was used to select features for DTI image classification (Zintgraf et al., 2017). Specifically,
prediction difference analysis is to estimate the importance of input pixels by calculating the
effect of removing information from the imaging on the class prediction precision (Zeiler &
Fergus, 2014).
A sliding window (patch) of 3 × 3 × 3 was applied through each image. The imaging
signals contained in the sliding window was taken as a feature. Each one 3 × 3 × 3 patch
was replaced by randomly sampled values from multivariate normal distributions. The
resulting new image where the imaging feature (information) was removed was input into a
previously trained CNN model to obtain probability 𝑝 for predicting AD. Let 𝑝 be the
probability of predicting AD using the original images (without removing the feature
(information)). The relative importance of the feature was evaluated by (Zintgraf et al., 2017)
𝑑 = 𝑙𝑜𝑔
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( 15 )

The sliding window moved across the entire image and a relevance matrix W of the
same size as the whole image was generated, which reflected the relevance importance of
all image pixels. A positive value indicated the pixel contributed evidence for the
classification of AD, whereas a negative value showed that the pixel contributed against the
classification of AD. For details, please see (Zintgraf et al., 2017).
3.2.6 Causal Discovery
Three-dimensional functional principal component scores (FPCs) were used to
summarize the imaging signal information of the brain region (M. Xiong, 2018). Similarly,
one dimensional FPCs can be used to summarize genetic information in the gene. ACTs
were used to discover causal relationships between the brain neuroimaging region and AD,
and causal relationships between the brain neuroimaging region and gene as well
(Goodfellow et al., 2014; Lopez-Paz & Oquab, 2016). Specifically, consider two variables
𝑋 and 𝑌, which can be binary disease status, or continuous FPCs summarizing imaging
signals in the brain region or genetic variation in the gene. If 𝑋 causes 𝑌, denoted by 𝑋 → 𝑌,
then we have
𝑌 = 𝑓 (𝑋, 𝑁 ) ,
where 𝑓 is a nonlinear function and realized by conditional GAN where a neural
network is used to approximate the nonlinear function 𝑓 (𝑋, 𝑁 ) , and 𝑁 is a noise random
variable and is independent of cause 𝑋. Similarly, if 𝑌 causes 𝑋 ( 𝑌 → 𝑋 ), then we have
𝑋 = 𝑓 (𝑌, 𝑁 ) ,
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where 𝑓 is a nonlinear function, and 𝑁 is a noise random variable and is
independent of cause 𝑌. Assume that 𝑛 subjects are sampled.
We define dataset 𝐷 = { 𝑢 , 𝑣 , 𝑖 = 1, … , 𝑛}. We assign label 0 to dataset 𝐷 =
{𝑢 , 𝑖 = 1, … , 𝑛} and 1 to dataset 𝐷 = {𝑣 , 𝑖 = 1, … , 𝑛} . Let 𝑃 be the distribution of 𝑢 , 𝑖 =
1, … , 𝑛 and 𝑄 be the distribution of 𝑣 , 𝑖 = 1, … , 𝑛

We use the K nearest neighbor (KNN)

as a binary classifier to classify two datasets and define the test statistic 𝑡 as the classification
accuracy to test the null hypothesis of equal distributions of two datasets 𝑃 = 𝑄. Let 𝑧 be a
random variable.
The procedures for causal discovery using ACTs are summarized as follows (LopezPaz & Oquab, 2016).
1.

Use a CGAN from 𝑋 → 𝑌 to generate the dataset 𝐷

→

= { 𝑥 ,𝑦 =

→

= {(𝑥 =

𝑓 (𝑥 , 𝑧 ) , 𝑖 = 1, … , 𝑛}.
2.

Use a CGAN from 𝑌 → 𝑋 to generate the dataset 𝐷

𝑓 (𝑦 , 𝑧 ), 𝑦 ), 𝑖 = 1, … , 𝑛}.
3.

Divide the total samples into training samples and test samples.

4.

Classify two datasets : 𝐷 = 𝐷 = { 𝑦 , 𝑖 = 1, … , 𝑛} versus 𝐷 = 𝐷

{ 𝑦 , 𝑖 = 1, … , 𝑛} and calculate the two-sample statistic 𝑡̂
5.

Calculate the test statistic 𝑇 = 𝑡̂

→

− 𝑡̂

→
→

→

=

.
. Under the null hypothesis of no

causal relationship or test inconclusive , the statistic 𝑇 is asymptotically distributed as
47

=

.

Classify two datasets : 𝐷 = 𝐷 = {𝑥 , 𝑖 = 1, … , 𝑛} versus 𝐷 = 𝐷

{𝑥 , 𝑖 = 1, … , 𝑛} and calculate the two-sample statistic 𝑡̂
6.

→

→

𝑁(0, 𝜎 ) , where 𝜎 =

.

− 2𝑐𝑜𝑣(𝑡̂

→

, 𝑡̂

→

),𝑛

is the number of subjects in

the test set.
4. Human Subjects, Animal Subjects, or Safety Considerations
The datasets I will use include the Alzheimer’s Disease Neuroimaging Initiative
(ADNI, adni.loni.usc.edu) and The Cancer Genome Atlas Program (TCGA,
https://portal.gdc.cancer.gov/). Both of these datasets are de-identified and available to the
public. My request to use the datasets have been approved by my dissertation advisor Dr.
Momiao Xiong.
RESULTS
1. Simulation Experiments for ITE Estimation
Statistical simulations were conducted to evaluate the performance of the proposed
algorithm, in comparison with linear regression, propensity score method, k nearest neighbor
regression and random forest, when the treatment is binary. Synthetic data was generated for
three scenarios. Scenario I corresponds to the simple case when the covariate that affects ITE
has only a single dimension. Scenario II corresponds to the case when the ITE distribution is
affected by some high-dimensional feature with complex structure.
Table 2 listed the quantitative results comparing CFGAIN and other state-of-art
methods for scenario I. Based on the results, random forest and the proposed CFGAIN had
the best performance in terms of PEHE and MSE, which were much smaller than the
estimates from ordinary linear regression (OLS), despite the latter was the standard analytical
method used in such case of a randomized control trial with a continuous outcome. In
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addition, the true and estimated ITEs were plotted against the covariate x (Figure 7). It could
be clearly visualized that true ITEs vary according to values of x and CFGAIN was able to
capture the variation, whereas the ordinary linear regression could only estimate the ATE
without acknowledging any of the causation between x and ITE.
Table 3 listed the quantitative comparison between the proposed method and other
state-of-art methods for scenario II. In this comparison, fully connected layers and
convolutional layers were used for encoding purpose, given the fact that the highdimensional covariate X were generated. The results clearly showed that the proposed
method outperformed other methods, which had the closest estimated PEHE to the ground
truth and the smallest MSE. In addition, due to the graphical nature of the high dimensional
covariate X, encoding with convolutional layers performed better in comparison with
decoding with fully connected layers. Despite the fact that random forest outperformed
CFGAIN in the previous simulation setting where the covariate x was a simple onedimensional vector, CFGAIN has been proven to be more accurate when the true ITE is
affected by complex and high dimensional covariates.
To better visualize the results for scenario II, estimated ITE was plotted against true
ITE to check the consistency of the two (Figure 8). If the estimated ITEs were close to the
ground truth, all data points should roughly follow along the 45 degree reference line without
any curvature. It could be clearly shown that AEGAIN with convolutional encoding had the
best performance whereas other methods all displayed some deviation from the 45 degree
line.
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2. Simulation Experiments for ACT
Statistical stimulation was conducted using synthetic data to evaluate the type I error
and power of the proposed test. Three different scenarios were explored. Type I error is
defined the probability of significant results at a pre-specified significance level when the
null hypothesis of no causation should not be rejected. Power is defined as the probability of
successfully rejecting the null hypothesis of no causation when there is causation. Power of
correctly identifying the causation direction was also calculated. Scenario I corresponds to
the case where there is no association and no causation. Scenario II corresponds to the case
where X and Y are associated but no causation. Scenario III corresponds to the case where X
and Y have causal relations.
Table 4 listed type I errors calculated from scenario I – no association and causation.
Type I errors were fluctuated around nominal levels. When the nominal level was set to 0.05,
the larger the sample size, the closer to 0.05 for the type I error. Similarly, Table 5 listed type
I errors when there is association but no causation. Type I errors were also fluctuated around
nominal levels. When the nominal level was set to 0.01, the larger the sample size, the closer
to 0.01 for the type I error.
Power was calculated for varying sample sizes (Figure 9). As expected, the power of
ACT increased from 0.67 to 0.90 as sample size increased from 200 to 5000 (Table 6).
However, the range of power clearly depended on the type of nonlinear transformation used.
Power was greatly reduced when the complexity of non-liner transformation was changed
from quadratic function (Y= X2 +N) to cubic function (Y= 4X3 +N) (Table 7). In addition, it
was generally more difficult to detect the correct direction of causation even after
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establishing a significant causation between two variables, as proved by the lower power for
direction identification (Table 8 and 9).
3. Application Studies
3.1 ITE Estimation for TCGA
3.1.1 Simulation Results
Previous CFGAIN simulation applied to a more general case of high dimensional
covariate, but did not specifically address gene expression data, so I conducted another
simulation study by borrowing gene expression profiles from TCGA pancreatic cancer
studies. In this simulation, I randomly selected 1000 genes from around 60,000 genes
available in the TCGA datasets, and assumed that these 1000 genes affected true ITE
distribution through some nonlinear function:
𝐼𝑇𝐸 = 𝑓(1000 𝑠𝑒𝑙𝑒𝑐𝑡𝑒𝑑 𝑔𝑒𝑛𝑒𝑠)
The outcome here was continuous and the baseline levels were sampled from exponential
distributions. The method section listed details about the data generation process.
I first treated 1000 selected genes as input into all methods to compare the accuracy
of estimation. Table 10 listed all the quantitative measures. ATE, ATT and ATC were
included as sanity checks to confirm if the method at least estimated the averages accurately.
While most of methods were able to give a close estimate of the average effects, it was worth
noting that K nearest neighbor did poorly in this task, which was very likely due to the fact
that Euclidean distance used in KNN could not accommodate the complexity of the nonlinear effect of genes. MSE was used as the index to assess the accuracy of ITE estimation.
51

It was clear that CFGAIN outperformed all other methods by a large amount, indicating it
was able to give the most accurate estimation of ITEs. Figure 10 plotted the true and
estimated ITE distributions against one of the genes whose value had the largest variance. It
can be clearly visualized that CFGAIN’s estimated ITEs distribution was much more close to
the ground truth, whereas other methods’ estimation was more scattered.
Previous analysis did not involve any feature selection/engineering. In most of the
cases, we could not narrow down to only a few genes that affect the ITEs, so feature
selection is necessary before any treatment effect estimation. To select the most relevant
features for the outcome, linear regressions were performed for each of genes, with the
factual outcome as the dependent variable and treatment assignment as the other independent
variable: 𝑦 = 𝛼 + 𝛽 ∗ 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 + 𝛽 ∗ 𝑔𝑒𝑛𝑒 + ℇ, ℇ~𝑁(0, 𝝈𝟐 ). P-values for 𝛽 were
sorted and top 1000 genes with the lowest p-values were selected as important features to be
included into multiple, linear regression, propensity score, KNN and random forest to
estimate ITEs. In contrast to this, given the complexity and high dimension of gene
expression data, convolutional auto-encoder was used in conjunction with CFGAIN to
perform automatic feature engineering and ITE estimation. Table 11 listed the quantitative
results. Only CFGAIN and random forest were able to estimate the average effects relatively
accurately, whereas linear regression, propensity score and KNN’s estimation was biased. In
addition, CFGAIN once again had the smallest MSE of 0.6970, ten times smaller than linear
regression, which gave the largest MSE due to its non-flexibility. We could visualize the
same results in Figure 11. GAIN’s estimated ITE distribution was more close to the ground
truth, in comparison with other methods, whose values were more scattered. We did not see a
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complete overlap between the ground truth and the estimation because of estimation error
and the random noise introduced in the data generation process.
3.1.2 ITE Estimation for Lung Cancer
CFGAIN was applied to estimate ITE in days to death from different treatment
strategies on lung cancer patients. TCGA (https://www.cancer.gov/aboutnci/organization/ccg/research/structural-genomics/tcga) is a large-scale cancer genomics
program, supported by the National Cancer Institute (NCI) and the National Human Genome
Research Institute. It was initiated in 2006 and included extensive genomic, epigenetic,
transcriptomic and proteomic data for over 33 cancer types. The TCGA lung cancer data
used in this study included samples from three projects: TCGA-LUSC, TCGA-LUAD and
TCGA-MESO. After merging clinical information, treatment strategies and days to death, a
sample of 186 subjects with complete data was used for this analysis. Their expression
profiles of 60,483 genes were extracted to be used as covariates to estimate ITE. Among the
study subjects, 80 subjects had chemotherapy only and 39 subjects had radiation therapy
only, whereas 67 subjects had combinational therapy of both chemotherapy and radiation.
Demographic and clinical factors that were also used for ITE estimation included age at
diagnosis, gender, race, ethnicity, diagnosis, tumor stage, tumor morphology, tumor origin
and which project the subject belonged to.
Over 60,000 gene expression values were encoded into a vector of 128 latent factors.
To increase the efficiency of information processing by CFGAIN, gene expression values
were arranged into a 2X2 matrix in size of 236x238 with padding 0s in the end. Then
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convolutional filters were used in the auto-encoder part of CFGAIN. To ensure fair
comparisons, the 128 latent factors were used to summarize information from gene
expression profiles for all methods.
Plug-in validation PEHE was presented in Table 12. Since ITE was defined as the
difference between two treatment arms, so three pairwise comparison was conducted to
calculate ATE, ATT and ATC. It was worth noting that CFAIN was one of the top 2 best
methods for all three pairwise comparisons. For the comparison between chemo-therapy vs.
combinational therapy, random forest had the lowest PEHE, indicating its best accuracy to
quantify the ITEs, whereas CFGAIN came to the second place. However, for the other two
comparisons, CFGAIN provided the smallest PEHE, which made it most suitable for this two
comparisons.
Table 13-15 listed the results of applying CFGAIN on TCGA lung cancer data. As
stated previously, random forest was chosen as the analytical method for the comparison
between chemotherapy and combination, people receiving chemotherapy were estimated to
live 0.14 standard deviation longer than people receiving combinational therapy on average
(Table 13). Similarly, for the comparison between radiation and combination therapy, people
receiving radiation were estimated to live longer than people receiving combination therapy
on average (Table 14). Last but not least, the results from CFGAIN indicated that people
receiving chemotherapy would live longer than people receiving radiation on average,
controlling for clinical factors (Table 15).
After getting the complete outcome vectors, ITE was calculated for each subject. The
treatment therapy corresponding to the longest survival days was chosen as the recommended
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treatment (Table 16). KNN, random forest and linear recommended more patients to
radiation therapy, which was different from the observed distribution for the treatment
strategies, indicating possible misplacement of patients to suboptimal treatment strategies.
On contrary, CFGAIN recommended more patients to chemotherapy, which was the closest
to the therapies that they actually received clinically.
To further understand which latent factors and genes played important roles for ITE,
lasso regression with 5-fold cross validation was performed by regressing ITE estimates
against latent factors. After important features were selected, multiple linear regression was
performed on ITE vs. selected features and R2 was reported (Table 17). For all three pairs,
selected latent factors explained around 40% of variance in ITE, indicating the predictive
power of gene expression profiles. In addition, after clinical covariates were added, R 2 was
increased for all three pairwise comparisons, especially for radiation therapy in comparison
with the other two treatments.
To further understand the relations between latent factors and genes, Spearman
correlation was calculated for each of the genes and each of the latent factors selected from
Lasso regression. Genes that were significantly associated with latent factors were presented
in Table 18. Several EGFR-related genes were related to several latent factors. EGFR-AS1
was related to factor 101 (p-value=0.0076). ELDR was significantly associated with factor 51
(p-value=0.0063), factor 99 (p-value=0.0182) and factor 87 (p-value=0.0126).
3.2 Causal Discovery for Alzheimer’s disease
3.2.1 AD classification and prediction
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The network with 3D filters was used for classification and prediction of AD using 3D
whole brain DTI images at 4 different time points: baseline, 6 months, 12 months and 24
months. We consider two classes: AD and NC. AD prediction accuracy using 3D-CNN was
listed in Table 16 and its sensitivity and specificity in Table 17 where the left and right in the
brackets represented sensitivity and specificity, respectively. Tables 19 and 20 demonstrated
that the prediction accuracy, sensitivity and specificity of the model using the training dataset
at baseline to predict AD in the test datasets at baseline, 6 months, 12 months and 24 months
were 0.8675 (0.6873, 0.9600), 0.8452 (0.6364, 0.9600), 0.8335 (0.7295, 0.8995), 0.7463
(0.6294, 0.8853), respectively. In other cases, we can observe similar results. The AUC using
the training data at baseline, 6 months, 12 months and 24 months for prediction of AD in the
test datasets at the same time points, was 0.8571, 0.8291, 0.8583, and 0.7756, respectively.
The low sensitivity of prediction of AD may be due to small and imbalanced sample size (51
AD and 100 controls). Much higher proportion of non-AD controls) decreased sensitivity,
while increased specificity. Deep 3D-CNN that has a large number of parameters to be
estimated requires large sample sizes. Although we used data augmentation methods to
increase sample sizes, augmentation methods still did not provide large and reliable sample
sizes. Large sample sizes is an important issue for increasing the prediction of accuracy.
3.2.2 Region selection and interpretation
Relative importance of value 𝑑 was sorted. Image areas whose relative importance
value were in the top 10th percentile were considered as features that contributed substantially
to the prediction of AD. We identified 23 important brain regions that contributed
56

substantially to AD prediction. The results were shown in Figure 12 where each sub-figure
had 91 × 109 pixel sizes where the darker the red color is, the more important the brain
region is to the prediction accuracy. The brain regions with red color included the temporal
lobe (the left temporal lobe, medial, and right temporal lobe), ventricles and enlarged
ventricle, occipital lobe and prefrontal area. To further interpret the image analysis results
and increase their transparency, we tested the causal relationships between DTIs image ROIs
and AD disease at baseline, 6 months, 12 months and 24 months using CGAN-based
statistics. After Bonferroni correction, P-value < 0.0022 was threshold to declare
significance. The number of identified brain regions that showed significant causation to AD
at baseline, 6 months, 12 months and 24 months were 1, 1, 2, and 4, respectively. Table 21
listed ROIs where p-values for testing causation between the ROI and AD were less than
0.05. Three remarkable features emerged from these results. First, as time passed, AD
progressed from mild (early stage), via moderate (middle stage), to severe (late stage) which
resulted in atrophy of more and more brain regions. Therefore, we observed the increased
number of significant causal brain regions with AD as the study time of AD increased from
the baseline to 24 months. Second, in general, as AD progressed, the significance of
causation between the brain region and AD increased (p-values for testing causation
decreased). Third, the brain region ROI 18 (the ventricles and enlarged ventricle) (Figure 13)
showed significant causation to AD at all four time points (baseline, 6 months, 12 months
and 24 months). The brain regions ROI 14 (the left temporal lobe) (Figure 13) showed
significant causation at 12 months and 24 months after Bonferroni correction. The literature
reports that these regions are related to AD. The left temporal lobe is involved in language
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and AD (Cretin, Di Bitonto, Blanc, & Magnin, 2015; Flick et al., 2018; Trimmel et al.,
2018), the right temporal lobe atrophy is involved in severe impairment in emotion
recognition (Everhart, Watson, Bickel, & Stephenson, 2015) and causes frontotemporal
dementia (Gliebus, 2014), with the brain ventricles often affected AD (Ferrarini et al.,
2006).Ventricle enlargement is a useful structural biomarker for the diagnosis of AD
(Anandh, Sujatha, & Ramakrishnan, 2014).
3.2.3 Genetic studies of two brain regions
To uncover genetic architecture of brain regions, in addition to genetic imaging
association analysis, we conducted genetic imaging causal analysis using ACT where
imaging signals within the brain region and SNPs within the gene were summarized by two
dimensional functional principle scores and classical functional principle scores, respectively
(Lopez-Paz & Oquab, 2016). The total number of candidate genes being tested was 61. After
Bonferroni correction, p-value for declaring significance of both causation and association
was 0.00082. We presented the results of P-values < 0.05 in causal analysis and association
analysis of genetic variation in 61 candidate genes with two brain regions: left temporal lobe
and frontal and temporal left lobe, and right temporal lobe as seen in Tables S1 and S2,
respectively, where 61 genes were obtained from genome-wide causation studies of AD in
the manuscript (Lin et al., unpublished). In Tables S1 and S2, the P-values in green bold
denoted significant causation or association after Bonferroni corrections. The majority of
genes that had causal or association relationships with brain neuroimaging phenotypes were
identified at all time points (baseline, 6 months, 12 months and 24 months). We also
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observed that these identified genes had causal or association relationships with both the left
temporal lobe and right temporal lobe regions. The identified genes CD33, COBL and APP
that had causal relationships with brain neuroimaging regions were confirmed multiple times
in the literature (Bradshaw et al., 2013; C.-C. Huang et al., 2019; C.-Y. Huang et al., 2019;
Kovacs, Burchett, & Sheafor, 2018; Mez et al., 2017; Van Giau et al., 2018). It was also
reported that gene FGF4 was involved in neurodevelopmental disorders (Grillo et al., 2014),
FRMD6 was implicated in AD (Hong et al., 2012), Dock9 played an important role in
regulation of morphological changes in hippocampal neurons (Kuramoto, Negishi, & Katoh,
2009), H3F3B was associated with a broad schizophrenia phenotype (Manley et al., 2018),
SCYL1 was involved in cerebellar atrophy (Lenz et al., 2018), AKAP5 played a significant
role in the regulation of sympathetic nerve activities (Han et al., 2016), and PIGC was
involved in epilepsy and intellectual disability (Edvardson et al., 2017).
DISCUSSION
1. ITE-Related Genes
The genes identified in this dissertation that were associated with ITEs were also
confirmed in literature as important cancer genes or prognostic markers. Recent studies
found that TRIM32 not only had an impact on chemo-resistance to breast cancer cells
through NF-κB signaling (Zhao et al., 2018), but also negatively regulated tumor suppressor
gene p53 to contribute to tumorigenesis (J. Liu et al., 2014). HOXB5 was shown negatively
affected cell proliferation, migration and invasion in non-small cell lung cancer (B. Zhang,
Li, & Zhang, 2018), but acted as an oncogenic driver in breast cancer and head and neck
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carcinoma (J.-Y. Lee et al., 2015; K. Lee et al., 2019). AMIGO2 upregulation promoted
metastatic tumor cells to attach to lover endothelial cells and has been considered as a novel
target for cancer (Fontanals-Cirera et al., 2017; Kanda et al., 2017). Researchers have also
found that overexpression of IGSF10 genes was significantly associated with good prognosis
for lung cancer patients, indicating a possible prognostic marker for treatment evaluation
(Ling et al., 2020). In addition to protein-coding genes, the expression level of long
noncoding RNA (lncRNAs) was found to be associated with heterogeneous prognosis in this
study, which has also been consistent with previous findings (Sun et al., 2019). The
epidermal growth factor receptor antisense RNA 1 (EGFR-AS1) was found to be associated
with a poor prognosis in patients with non small cell lung cancer and renal cancer, which
could be attributed to overexpression of EGFR-AS1 induced chemotherapy resistance (Tan et
al., 2017; Xu, Tu, Zhao, Xie, & Tang, 2019). Moreover, I also identified that AL092794.1, an
antisense to KRAS, was significant associated with ITE distribution. KRAS mutation was
established as the major driver of lung cancer cell growth and has been playing a very
important role in genetic counselling and treatment selection for patients (Eberhard et al.,
2005; Riely, Marks, & Pao, 2009).
The greatest challenge for machine-learning based methods to be applicable in real
datasets for ITE estimations lies in the inaccessibility of counterfactuals. In this project, I
used the plug-in validation, which synthesized complete outcome vectors based on observed
data. However, plug-in PEHE estimates can only reveal their true comparative performance
when the plugged-in distribution and the true distribution are close enough, i.e. 𝑇 − 𝑇
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≈

0 (A. Alaa & Van Der Schaar, 2019). This assumption is difficult to test because we do not
have access to the ground truth. Alaa et al. recently proposed to use the influence statistics to
unplug from the plugged-in distribution to adjust the plug-in PEHE estimates(A. Alaa & Van
Der Schaar, 2019). Unfortunately they have not released enough details of their methods for
me to apply their method. Further research will be conducted to resolve the problem of model
validation without access to counterfactuals.
2. Causal Discovery for AD
In this dissertation, a general artificial intelligence (AI) platform for prediction of AD
using DTI images was presented. Non-transparency could be a major challenge of deep
learning for medical image analysis. To meet this challenge, we introduced three approaches
to medical image interpretation: feature selection and visualization, causal analysis of
neuroimaging region and genetic-imaging analysis. Feature selection and visualization
methods selected and visualized brain regions as a potential pathology of AD. Further ACT
tests discovered potential causal relationships between the brain neuroimaging regions and
candidate genes for AD. We observed the increased number of significant causal brain
regions with AD when AD progressed. In general, as AD progressed, the significance of
causation between the brain region and AD increased (p-values decreased). We observed the
ventricles and enlarged ventricle, left and right temporal lobes had strong causal relationships
with AD. Temporal lobes including the hippocampus are crucial in AD development at the
early stages, whereas the ventricles and enlarged ventricle are useful structural biomarker for
the diagnosis of AD. Joint causal analysis of genetic and images of left and right temporal
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regions using ACTs mapped CD33, COBL, FRMD6, APP and other genes to the left and right
temporal brain regions.
Many findings in the dissertation could be confirmed in the literature. For example,
both prediction analysis using deep learning and causal analysis using ACT identified brain
temporal lobe region that was involved in AD. Temporal lobe includes the hippocampus and
its surrounding regions. It is well-known that the temporal lobe consists of structures that are
vital for long-term memory. There are numerous reports that temporal lobe including left,
medial and right temporal lobe are involved in AD pathology (Delgado-González, FlorensaVila, Mansilla-Legorburo, Insausti, & Artacho-Pérula, 2017; Kakeda & Korogi, 2010; Li &
Chen, 2015; Menéndez-González, de Celis Alonso, Salas-Pacheco, & Arias-Carrión, 2015;
Wolk et al., 2017). DTI discovered the functional and structural connectivity between the
medial temporal lobes (MTL) and posteromedial cortex (PMC) (Buckner, Andrews-Hanna,
& Schacter, 2008; Pasquini et al., 2019). The MTL includes the hippocampal formation and
other cortices. These regions underlie memory processing through interplay with neocortical
areas from the PMC. AD-related pathological changes such as tau accumulation, amyloid-𝛽
deposition often affect the PMC and MTL regions. The functional and structural
disconnections between the MTL and PMC cause the development and progression of AD.
The literature confirmed the identified pathological paths from genetic variants to
AD via brain regions: CD33→Medial temporal and hippocampus (Wang et al., 2019) → AD
(Pasquini et al., 2019), and CD33→ AD (Miles et al., 2019); APP → medial and lateral
temporal lobe (C.-Y. Huang et al., 2019) → AD (Buckner et al., 2008), and APP → AD (Z.-d.
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Zhou et al., 2011); SCYL1→ Cerebellar Atrophy (Schmidt et al., 2015) → AD (Gallo et al.,
2017), and SCYL1→ neurodegenerative disease (Schmidt et al., 2007). These provided
indirect evidences of identified biomarkers for unravelling mechanism of AD.
CONCLUSION
In this dissertation, I addressed the causal inference problem through deep learning
approaches. A framework based on the generative adversarial networks was developed to
estimate the heterogeneous treatment effect using the well-established counterfactual
reasoning for causal inference (Hernán MA, 2019). In addition to this experimental design to
determine causation and its effect, I further explored the case where only retrospective
observational data was available to perform causal discovery between two sets of variables.
A novel causal test was proposed, which was inspired by the additive noise models (ANMs)
for causal discovery but with relaxed assumptions and great flexibility. A few applications of
developed methods to real datasets were also presented to showcase their usage, as well as to
stimulate further discussions regarding the great challenges we are facing in developing
robust deep learning platforms.
Given the popularity of machine learning, which are associational learning systems
(Pearl, 2019), it seems less obvious how causal inference could potentially improve artificial
intelligence. However, modern machine learning systems are facing several major obstacles
(Pearl, 2019). The first obstacle is the lack of robustness or reliability. Current systems often
fail miserably for new instances which they have not been trained for. They are optimized for
the current dataset, but it is quite difficult for the systems to transfer the knowledge to a new
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dataset. Another great difficulty is opacity or the lack of explainability. Current systems have
mostly been considered as ‘black-box’ algorithms. This non-transparency reduces people’s
trust towards such systems and thus limits their usage in practice. Last but not least, current
systems could not recognize cause-effect relations, which is considered as a necessary
component of human-level intelligence. Causal inference is able to provide some remedies to
all these difficulties, which helps to build stronger AI systems.
Just as causal inference has the potential to revolutionize machine learning, machine
learning is capable to empower modern causal inference. With the advances in graphical
models and structural equations, structural causal models (SCMs) have been established,
which serves as the ‘inference engine’ to solve sophisticated queries of interest (Pearl, 2019).
SCMs engine accepts assumptions (in the form of DAGs), data and queries of interest and
outputs an estimand (i.e. a procedure of estimation), an estimate (i.e. a consistent estimate of
the estimand) and fit indices which measure the compatibility of data and the model
assumptions. Many techniques have been operated under this framework such as propensity
score methods and tree-based methods (Austin, 2011; Lu et al., 2018). However, as data
complexity and volume increases, these techniques have their own limitations and deep
learning approaches are likely to outperform them, just as what have been shown in this
dissertation.
Deep learning approaches have a few remarkable strengths. One key strength is the
capability to handle high-dimensional complex data without manual feature engineering. For
example, I used auto-encoders to conduct automatic feature engineering and dimension
reduction, which reduced the whole gene expression profile to hundreds of latent factors. In
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addition, deep learning approaches have been adaptable to various form of data.
Convolutional neural networks have gained huge success in image recognition, a task that I
also explored using DTI images to classify Alzheimer’s cases in this dissertation. Recurrent
neural networks are specially designed for sequential data to accommodate the temporal
dependence. Moreover, deep learning approaches exhibits more flexibility in terms of
approximating non-linear functions than standard approaches. One typical example to
demonstrate this is the generative adversarial networks used in this dissertation. In contrast to
the additive noise models for causal discovery which assumes 𝑦 = 𝑓(𝑥) + 𝑛𝑜𝑖𝑠𝑒, GAN
essentially tries to learn the non-linear mapping of 𝑦 = 𝑓(𝑥, 𝑛𝑜𝑖𝑠𝑒), which is more generous
than the additive assumptions. Last but not least, deep learning approaches are generally
more suitable to unsupervised learning. In this dissertation, one of the greatest obstacle was
the lack of counterfactuals, which made ITE estimation an unsupervised problem. Although I
was able to apply a few machine learning techniques to get the estimation, they were
essentially supervised learning. Nevertheless, CFGAIN was based on the generative
adversarial networks, which were aimed to learn the distribution of the input data in an
unsupervised fashion. Therefore, CFGAIN is more respectful of the unsupervised nature of
this problem, in comparison of other methods.
Despite the advantages of deep learning, we need to pay special attention to its
limitations. First, deep learning approaches generally require large amount of data so that
they can learn from many examples and capture as much the association signals as possible.
However, human beings can perform object recognition with much less training using causal
reasoning. This further highlights the importance of incorporating causal inference into deep
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learning systems. Second, deep learning systems have always been criticized for nontransparency. In this dissertation, I tried to offset this by proposing a novel statistical test for
causal discovery, which could be conducted in order to understand a complex deep learning
system through causal analysis. The causal discovery analysis for Alzheimer’s disease serves
as an attempt to decode a deep learning system.
In conclusion, causal inference, in conjunction with deep learning approaches, is
crucial to exploit full potential of artificial intelligence. Further research is needed to explore
additional methods for heterogeneous effect estimation, causal discovery, missing data and
confounding issues, as well as how to incorporate causal inference into complex machine
learning systems in an effective and efficient way.
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Figure 1. An example of neural networks

Figure 2. The structure of a conditional generative adversarial network (CGAN).
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Figure 3. DAG for a randomized controlled trial

Figure 4. Causal DAGs for Observational Studies.
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Figure 5. Architecture of CFGAIN.

Figure 6. Procedure for conducting the proposed adversarial causal test (ACT).
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Figure 7. Comparisons of ITE results from linear regression and CFGAIN
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Figure 8. Comparisons of ITE results for different methods
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Figure 9. Power for ACTs at varying sample sizes. Cause X was randomly sampled from normal distribution and effect Y
was obtained through the non-linear transformation of X plus the random noise N: Y= f (X) +N. Quadratic and cubic
functions were used for the non-linear mapping.
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Figure 10. Comparisons of various methods for ITE estimation without feature selection.

Figure 11. Comparisons of various methods for ITE estimation with feature selection.
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Figure 12. Visualization of the brain regions with relative importance values at the baseline, 6 months, 12 months
and 24 months. The deeper red color of the brain region, the more important for AD prediction.
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Figure 13. Three brain regions showed causation to AD.
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Table 1. 3D filters in five convolutional layers.

Filter Size
11X11X11
5X5X5
3X3X3
3X3X3
3X3X3

Stride in (X,Y) direction
4
1
1
1
1

Stride in Z direction
4
1
1
1
1

Table 2. Comparisons of different methods for ITE using data generated in scenario I

Methods
Ground Truth
Conditional GAIN
OLS (t only)
OLS (t and x)
Propensity Score
KNN
Random Forest

ATE
0.1940
0.1898
0.2008
0.1990
0.1990
0.1943
0.1936

ATT
0.2020
0.1406
0.2008
0.1990
0.1990
0.1987
0.1972

ATC
0.1863
0.2367
0.2008
0.1990
0.1990
0.1900
0.1902

PEHE
0.1290
0.1165
0.0549
0.0549
0.0549
0.1119
0.1104

MSE
0.0
0.0295
0.0748
0.0557
0.0557
0.0212
0.0199

Table 3. Comparisons of different methods for ITE using data generated in scenario II

Methods
Ground Truth
Conditional GAIN (NN)
Conditional GAIN (CNN)
OLS (t and x)
Propensity Score
KNN
Random Forest

ATE
6.5385
7.0666
6.5531
6.5089
6.2813
6.2090
6.3046

ATT
6.6713
7.1156
6.7098
6.5556
6.3252
6.1913
6.4193
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ATC
6.4142
7.0207
6.4064
6.4651
6.2402
6.2255
6.1972

PEHE
2.0856
3.6481
1.4079
9.6378
10.0558
5.7457
4.0134

MSE
0.0
5.5315
3.1188
8.8863
9.3316
6.1478
6.0422

Table 4. Type I errors when there is no association or causation

Sample Size
Nominal Level
0.01
0.05

500

1000

2000

0.008
0.036

0.011
0.045

0.014
0.051

Table 5. Type I errors when there is association but no causation

Sample Size
Nominal Level
0.01
0.05

500

1000

2000

0.006
0.046

0.010
0.057

0.011
0.045

Table 6. Causation power for ACTs at varying sample sizes using the quadratic transformation.

Causation Power
Significance
level

0.05
0.01

200
0.67
0.61

Number of samples
1000
2000
0.80
0.85
0.72
0.82

500
0.68
0.60

5000
0.90
0.89

Table 7. Causation power for ACTs at varying sample sizes using the cubic transformation.

Causation Power
Significance
level

0.05
0.01

200
0.31
0.15

Number of samples
1000
2000
0.47
0.62
0.36
0.53

500
0.40
0.20
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5000
0.66
0.57

Table 8. Power for ACTs to correctly identifying causation direction at varying sample sizes using the quadratic
transformation.

Correct Direction Power
Significance
level

0.05
0.01

200
0.66
0.60

500
0.63
0.58

Number of samples
1000
2000
0.66
0.67
0.63
0.65

5000
0.72
0.71

Table 9. Power for ACTs to correctly identifying causation direction at varying sample sizes using the quadratic
transformation.

Correct Direction Power
Significance
level

0.05
0.01

200
0.31
0.15

500
0.34
0.20
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Number of samples
1000
2000
0.44
0.52
0.34
0.45

5000
0.52
0.48

Table 10. Comparison of different methods in simulation study

Methods
Ground Truth
CFGAIN
Linear
Regression
Propensity
Score
KNN
Random Forest

ATE
0.6295
0.6103
0.6169

ATT
0.6304
0.5919
0.6304

ATC
0.6285
0.6292
0.6032

MSE
0
0.2463
4.4341

0.6059

0.6466

0.5648

1.0260

0.2804
0.6096

0.3270
0.5942

0.2335
0.6251

1.2665
1.1007

Table 11. Comparison of different methods with feature selection

Methods
Ground Truth
CFGAIN
Linear
Regression
Propensity
Score
KNN
Random Forest

ATE
0.6295
0.6133
0.6325

ATT
0.6304
0.6284
0.7588

ATC
0.6285
0.5980
0.5052

MSE
0
0.6970
6.0497

0.6081

0.6749

0.5407

1.0425

0.3094
0.6306

0.4401
0.6392

0.1776
0.6220

1.2012
1.0742
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Table 12. Plug-in validation of different methods for TCGA lung cancer dataset

Chemo vs. Combo
Linear Regression
Propensity Score
KNN
Random Forest
Autoencoder+GAIN

Radiation vs.
Combo
1.4893
1.4044
1.4865
1.5066
1.2825

1.9838
2.0843
1.9502
1.6913
1.8408
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Radiation vs. Chemo
2.0630
1.8632
2.2115
2.0298
1.8538

Table 13. Chemotherapy (treatment) vs. Combinational therapy (control)

Linear Regression
Propensity Score
KNN
Random Forests
Auto-encoder+GAIN

ATE
0.0694
-0.0153
0.1137
0.1368
0.1900

ATT
0.2668
0.0310
0.3439
0.3615
0.3988

ATC
-0.1164
-0.0501
-0.0845
-0.0955
0.0196

*ATT denotes the average ITE effect for people in the chemotherapy group.
** ATC denotes the average ITE effect for people in the combinational therapy group.

Table 14. Radiation (treatment) vs. Combinational therapy (control)

Linear Regression
Propensity Score
KNN
Random Forest
Autoencoder+GAIN

ATE
-0.0185
0.0854
-0.0009
-0.1450
0.0532

ATT
0.1158
-0.0284
0.1435
-0.3695
0.0328

ATC
-0.1164
0.1879
-0.0845
-0.1142
-0.2528

*ATT denotes the average ITE effect for people in the radiation group.
** ATC denotes the average ITE effect for people in the combinational therapy group.

Table 15. Radiation (treatment) vs. chemotherapy (control)

Linear Regression
Propensity Score
KNN
Random Forest
Autoencoder+GAIN

ATE
-0.0879
0.1007
-0.1146
-0.2818
-0.1368

ATT
0.1158
0.0186
0.1435
-0.4631
-0.0376

ATC
-0.2668
0.0217
-0.3439
-0.4213
-0.0678

*ATT denotes the average ITE effect for people in the radiation group.
** ATC denotes the average ITE effect for people in the combinational therapy group.
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Table 16. Counts for Observed/Recommended Treatment on entire dataset

Observed
Linear Regression
Propensity Score
KNN
Random Forest
CFGAIN

Chemotherapy

Radiation

80
20
53
39
50
70

39
108
53
70
91
55

Combinational
therapy
67
58
80
77
45
61

Table 17. Feature selection using lasso* and R-square using selected features

Pairwise comparison

R-squared with
R-squared with
selected latent factors selected latent
for gene expression
factors for gene
expression +
clinical factors**
0.4128
0.4713

Chemotherapy vs.
Combination
Radiation vs.
0.4261
0.6559
Combination
Radiation vs.
0.3781
0.5335
Chemotherapy
*Five-fold cross validation was used with Lasso to determine the best alpha.
**Clinical factors refer to age at diagnosis, gender, race, ethnicity, diagnosis, tumor stage,
tumor morphology, tumor origin and which project the subject belonged to.
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Table 18. Selected significant correlations between latent factors and genes

Gene names

Gene descriptions

TRIM32

tripartite motif containing 32

HOXB5

homeobox B5
[Source:HGNC
Symbol;Acc:HGNC:5116]
adhesion molecule with Ig
like domain 2
immunoglobulin superfamily
member 10
WASP homolog associated
with actin, golgi membranes
and microtubules
endogenous Bornavirus like
nucleoprotein 1
olfactory receptor family 52
subfamily B member 2
EGFR-coamplified and
overexpressed protein
(ECOP) pseudogene

AMIGO2
IGSF10
WHAMM
EBLN1
OR52B2
AC241585.1

EGFR-AS1
ELDR

TP53TG3GP

CDKN2A-DT

EGFR antisense RNA 1
[Source:HGNC
Symbol;Acc:HGNC:40207]
EGFR long non-coding
downstream RNA
[Source:HGNC
Symbol;Acc:HGNC:49511]
TP53 target 3 family
member G, pseudogene
[Source:HGNC
Symbol;Acc:HGNC:51818]

CDKN2A divergent
transcript [Source:HGNC
Symbol;Acc:HGNC:23831]
83

Correlated latent
factors
20
98
86

P-values
3.8265 x10 -5
4.3738 x10-8
2.4997 x10-4

125

1.4361 x10-4

17

4.3097 x10-4

119

5.8337 x10-7

5

9.7148 x10-4

123

2.3129 x10-4

20
36
84
87
125
101

0.0020
0.0030
4.4538x10-5
0.0006
0.0083
0.0076

51
99
87

0.0063
0.0182
0.0126

11
75
78
97
107
123
20
16
36

0.0057
0.0280
0.0072
0.0112
0.0046
0.0087
8.8294 x10-4
1.0053 x10-3
0.0049

AL092794.1
AL021407.3
TPRKBP1

CDKN2AIPNLP1

SMAD1-AS1

SMAD5-AS1
AC125611.2
AC126471.1

AC068044.1

antisense to KRAS
PERP, TP53 apoptosis
effector (PERP) pseudogene
TP53RK binding protein
pseudogene 1
[Source:HGNC
Symbol;Acc:HGNC:44943]
CDKN2A interacting protein
N-terminal like pseudogene
1 [Source:HGNC
Symbol;Acc:HGNC:39854]
SMAD1 antisense RNA 1
[Source:HGNC
Symbol;Acc:HGNC:49379]

SMAD5 antisense RNA 1
[Source:HGNC
Symbol;Acc:HGNC:30586]
FGFR1 oncogene partner 2
(FGFR1OP2) pseudogene
p53 and DNA-damage
regulated 1 (PDRG1)
pseudogene

Mdm2, transformed 3T3 cell
double minute 2, p53
binding protein (mouse)
(MDM2) pseudogene
84

100
83
42

0.0191
4.8675 x10-2
0.0115

122

0.0062

112

0.0085

3
7
8
16
28
43
54
60
75
84
105
107
112
119
123
79
101

6.7220x10-4
0.0070
0.0013
0.0054
0.0341
0.0269
0.0045
0.0136
0.0067S
3.0237 x10-4
0.0011
0.0087
0.0080
5.7954 x10-4
0.0062
6.8549 x10-4
0.0066

108
119
24
28
75
86
92
122

0.0025
4.8342 x10-4
0.0045
0.0347
0.0295
0.0148
0.0030
0.0145

AC008126.1
NOP53-AS1

H3F3AP6

AC355297.1
H3F3AP4

H3F3AP4

AL109618.3
AL627095.1

PTENP1

AC006600.1

Mdm2 p53 binding protein
homolog (mouse) (MDM2)
pseudogene
NOP53 antisense RNA 1
[Source:HGNC
Symbol;Acc:HGNC:51587]

H3 histone, family 3A,
pseudogene 6
[Source:HGNC
Symbol;Acc:HGNC:42982]
H3 histone, family 3A
(H3F3A) pseudogene
H3 histone, family 3A,
pseudogene 4
[Source:HGNC
Symbol;Acc:HGNC:42980]
H3 histone family member
3A pseudogene 2
[Source:HGNC
Symbol;Acc:HGNC:19823]
fibroblast growth factor
receptor 3 (FGFR3)
pseudogene
pseudogene similar to part of
fibroblast growth factor
receptor 3 (achondroplasia,
thanatophoric dwarfism)
(FGFR3)
phosphatase and tensin
homolog pseudogene 1
[Source:HGNC
Symbol;Acc:HGNC:9589]
phosphatase and tensin
homologphosphatase and
tensin homologphosphatase
and tensin homolog (PTEN)
pseudogene
85

67

0.0205

13
37
51
58
63
64
68
106

0.0013
6.8694 x10-4
0.0023
0.0011
2.8379 x10-6
7.1582 x10-5
7.8089 x10-4
0.0118

36

0.0101

46
65

0.0189
0.0048

39
110

0.0054
0.0017

61

0.0017

9

0.0066

9
108

0.0031
0.0030

34

0.0106

Table 19. AD prediction accuracy on five-fold cross validation.

Model Development Time Point

Prediction Time Point
6 months
12 months
0.9123
0.8864
0.8452
0.8963
0.8335

Baseline
0.8675

Baseline
6 months
12 months
24 months

24 months
0.7967
0.7791
0.7813
0.7643

Table 20. Average sensitivity and specificity over five-fold cross validation

Model Development Time
Point
Baseline
6 months
12 months
24 months

Prediction Time Point
Baseline
(0.6873, 0.9600)

6 months
(0.8073, 0.9700)
(0.6364, 0.9600)
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12 months
(0.7524, 0.9717)
(0.7778, 0.9717)
(0.7295, 0.8995)

24 months
(0.6465, 0.9313)
(0.5977, 0.9417)
(0.6674, 0.8833)
(0.6294, 0.8853)

Table 21. Causations between DTIs image ROIs and AD disease status

Time Point
Baseline

ROI Index
2
18

P-value
0.0463
0.0005

6 months

8
14
17
18

0.0182
0.0108
0.0155
0.0010

12 months

6
14
17
18

0.0117
0.0018
0.0107
<0.00005

24 months

0
0.0245
3
0.0133
5
0.0092
7
0.0063
8
0.0030
9
0.0007
11
0.0084
12
0.0002
13
0.0082
14
<0.00005
15
0.0098
17
0.0239
18
<0.00005
19
0.0210
21
0.0363
22
0.0166
ROI 14 corresponds to the left temporal lobe and 17 corresponds to the right temporal lobe.
ROI 18 corresponds to ventricles and enlarged ventricle indicates atrophy of cerebral nerve
tissue, which is typical in AD patients.
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APPENDICES
Table S1. P-values of 43 genes that showed causation or association or both with the frontal,
left temporal lobe.

Baseline
P-Value

Gene

FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
APP
CD33
FRMD6
LIPE.AS1
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
SCYL1
RPL35P9
RN7SKP298
RP11.394D2.1
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5

Causal
Temporal_L Frontal &
Temp_L
6.8E-05
1.6E-04
4.9E-03
5.7E-03
3.9E-03
2.1E-03
3.6E-02
6.6E-03
5.1E-03
8.4E-04
5.0E-04
1.0E-03
1.5E-04
2.2E-02
7.2E-04
3.8E-05
2.9E-04
3.7E-03
1.2E-04
2.7E-02

5.1E-04
3.0E-02
1.8E-02
6.5E-03
2.2E-02
1.1E-03
6.9E-04
7.5E-05
2.9E-04
1.3E-02
1.2E-02
9.4E-04
1.5E-02

Association
Temporal_L Frontal &
Temp_L

1.9E-02

4.4E-02

4.6E-02

4.6E-03

5.9E-04
4.1E-02
9.6E-03

5.3E-03
2.5E-05
2.8E-04
1.8E-02
1.6E-02
7.5E-03
4.6E-02
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8.4E-03

RP11.732M18.2
CARS
PKDCC
ZBTB1
AKAP5
RP11.15F12.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
COBL
RP11.443B20.1
NBR1
PIGC

2.5E-03

3.0E-02

2.9E-02
8.2E-03
1.8E-04
2.2E-03

1.3E-03
1.2E-03
4.7E-03

1.0E-04

6.9E-04

2.6E-05

3.3E-04
1.7E-02
1.1E-03
6.9E-03

3.0E-02

2.5E-03
4.7E-03

2.8E-05
4.8E-03

2.4E-02

8.5E-03

1.3E-03
3.0E-02
3.0E-02

3.8E-02

2.6E-04

6 Months
Gene

FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
APP
CD33
FRMD6
LIPE.AS1
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
SCYL1
RPL35P9

P-Value
Causal
Temporal_L Frontal &
Temp_L
4.5E-05
1.0E-04
1.0E-02
6.8E-03
1.3E-03
1.8E-04
3.1E-02
6.6E-03
1.2E-02
8.4E-04
4.6E-04
4.1E-04
1.7E-04
1.8E-02
4.9E-02
3.0E-04
4.8E-05
3.2E-04
1.1E-03
5.5E-04
3.3E-02
3.1E-02
8.1E-03
5.7E-03
5.1E-04
6.7E-03
1.8E-02
4.8E-02
8.9E-03
4.4E-02
1.1E-03
1.8E-04

113

Association
Temporal_L Frontal &
Temp_L

3.1E-02

3.8E-02

RN7SKP298
RP11.394D2.1
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
CARS
PKDCC
ZBTB1
AKAP5
RP11.15F12.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
COBL
RP11.443B20.1
NBR1
PIGC

6.7E-05
1.0E-03
1.6E-04
2.4E-03
1.2E-02
7.4E-03
8.9E-04
8.6E-03
2.5E-03
2.5E-02

5.2E-03
8.6E-06
6.9E-04
1.7E-03
1.6E-02
4.6E-02
4.7E-03
3.3E-02
3.4E-02
3.0E-02

5.5E-04
3.7E-05

5.1E-04
4.2E-03
1.9E-03

4.0E-05

3.8E-04

7.3E-05

1.8E-02

2.9E-02
3.1E-04
9.0E-03
1.4E-03
1.2E-02

3.4E-02

1.6E-03
5.6E-03

2.1E-05
5.4E-03

9.7E-03

8.3E-03

4.1E-03
1.5E-02
4.0E-02

5.0E-02

1.0E-04

3.8E-02

4.1E-02

12 Months
Gene

FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P

P-Value
Causal
Temporal_L Frontal &
Temp_L
2.5E-05
1.0E-04
6.4E-03
8.5E-03
1.3E-03
1.8E-04
3.8E-02
3.6E-03
1.7E-02
1.4E-03
6.6E-04
4.1E-04
2.7E-04
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Association
Temporal_L Frontal &
Temp_L

3.5E-02

APP
CD33
FRMD6
LIPE.AS1
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
SCYL1
RPL35P9
RN7SKP298
RP11.394D2.1
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
CARS
PKDCC
ZBTB1
AKAP5
RP11.15F12.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
COBL
RP11.443B20.1
NBR1
PIGC

5.5E-04
1.3E-04
5.5E-04
3.1E-02
1.0E-03
5.1E-04
2.8E-02
4.2E-03
3.0E-03

6.7E-05
6.9E-04
3.0E-04
2.4E-03
1.2E-02
7.1E-03
1.6E-03
8.6E-03
8.2E-03

4.1E-03
4.9E-02
3.2E-04
1.1E-03
4.9E-02
1.6E-02
5.7E-03
6.7E-03
3.6E-02
3.2E-04
2.5E-03
8.6E-06
6.9E-04
1.7E-03
2.3E-02
4.6E-02
2.9E-03
3.4E-02
3.0E-02

3.0E-02
7.2E-04
5.4E-05

1.3E-03
6.4E-03
6.9E-04

2.7E-05

3.8E-04

1.8E-05

3.9E-02

1.8E-02

3.4E-02
3.7E-04
8.0E-03
1.2E-03
1.1E-02

3.5E-02

1.2E-03
5.2E-03

2.1E-05
4.9E-03

8.4E-03

8.7E-03

4.7E-03
1.3E-02
4.4E-02

4.9E-02

6.4E-04

24 Months
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4.4E-02

Gene

FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
APP
CD33
FRMD6
LIPE.AS1
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
SCYL1
RPL35P9
RN7SKP298
RP11.394D2.1
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
CARS
PKDCC
ZBTB1
AKAP5
RP11.15F12.1
FAM162B
YTHDC2

P-Value
Causal
Temporal_L Frontal &
Temp_L
5.7E-05
1.0E-04
2.6E-02
6.8E-03
3.7E-05
1.3E-03
2.3E-03
6.6E-04
2.0E-04
2.0E-02
7.9E-04
2.0E-04

7.4E-03
7.2E-04
2.2E-02
5.9E-03
6.0E-03
2.1E-02
6.6E-05
3.7E-04
1.5E-03
9.2E-04
1.0E-02
7.2E-03
2.0E-03
1.3E-02
7.7E-04

1.3E-03
2.0E-05

Association
Temporal_L Frontal &
Temp_L

1.7E-02
8.4E-04
4.3E-04
4.1E-03
4.9E-02
5.1E-04
5.7E-04
3.4E-02
3.1E-02
5.7E-03
4.6E-03
3.3E-02
3.6E-02
3.2E-04
3.6E-03
8.6E-06
6.9E-04
2.1E-03
2.6E-02
4.6E-02
2.9E-03
2.3E-02
1.8E-02
4.3E-02

1.3E-03
1.1E-02
3.0E-03
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3.9E-02

1.8E-02

4.8E-02

8.4E-04
4.6E-03
7.7E-04
1.0E-02

3.5E-02

4.0E-04

2.0E-05

LINC00926
CCDC179
RP11.84C13.2
COBL
RP11.443B20.1
NBR1
PIGC

8.9E-04
5.0E-05

3.8E-03

5.3E-03

6.7E-03

8.6E-03

3.8E-04
6.4E-04
7.8E-03
6.1E-03
4.4E-02
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Table S2. P-values of 46 genes that showed causation or association or both with the right
temporal lobe region.

Gene
FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
CD33
FRMD6
LIPE.AS1
AKAP9
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
SCYL1
RPL35P9
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
SAA2
PKDCC
ZBTB1

Baseline
P-Value
Causation Association
5.3E-05
2.3E-03
1.2E-02
1.6E-04
5.1E-03
1.4E-04
9.2E-04
2.1E-02
2.3E-05
2.0E-04
3.4E-02
1.2E-02
1.5E-02
1.9E-02
2.0E-02
2.7E-03
1.5E-05
2.2E-04
1.7E-03
4.1E-03
2.8E-02
1.7E-03
3.0E-02
3.0E-02
1.2E-03

7.1E-03
3.2E-03
4.0E-02
2.1E-02
5.1E-03
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6 Months
Gene
FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
CD33
FRMD6
LIPE.AS1
AKAP9
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
SCYL1
RPL35P9
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
SAA2
PKDCC
ZBTB1

P-Value
Causation Association
2.9E-05
7.8E-03
1.4E-02
8.9E-05
6.1E-03
2.1E-04
1.5E-04
4.3E-03
5.8E-06
2.0E-04
1.7E-02
3.5E-02
2.9E-02
2.4E-03
1.3E-02
2.9E-02
7.1E-05
1.4E-02
3.1E-03
2.2E-02
3.3E-03
1.1E-03
8.6E-03
3.9E-02
7.5E-03

4.2E-02

3.1E-02
1.4E-02
3.2E-03
1.1E-02
5.8E-03

SLC9B2
AKAP5
CTD.2176I21.2
RP11.15F12.1
AC079896.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
HARS
COBL
RP11.443B20.1
NBR1
PIGC

5.4E-03
3.8E-02

1.3E-02

1.0E-02
6.4E-04
2.1E-03

3.4E-02
3.5E-02
3.6E-04
4.8E-04

1.0E-04
3.2E-03
4.0E-02
6.0E-05
3.4E-02

7.0E-04
5.7E-03
3.0E-02

SLC9B2
AKAP5
CTD.2176I21.2
RP11.15F12.1
AC079896.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
HARS
COBL
RP11.443B20.1
NBR1
PIGC

12 Months
Gene
FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
CD33
FRMD6
LIPE.AS1
AKAP9
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52

1.7E-02
1.4E-02
6.1E-03
3.8E-02

1.9E-02
3.9E-02
3.1E-03
4.1E-02
1.6E-03
1.3E-03

1.4E-04
3.7E-04

1.8E-05
9.8E-04
2.2E-05
1.4E-03
1.2E-03
2.3E-02

24 Months

P-Value
Causation Association
2.9E-05
2.9E-02
1.4E-02
8.9E-05
6.1E-03
1.2E-04
1.5E-04
4.3E-03
5.8E-06
2.0E-04

7.1E-03

Gene
FGF4
FOLR2
RNU6.1272P
AL021394.1
RP11.953B20.2
ANKZF1
RNU6.883P
CD33
FRMD6
LIPE.AS1
AKAP9
RP11.749H17.2
RP11.749H17.1
DOCK9.AS2
H3F3B
DDX52
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P-Value
Causation Association
1.6E-05
7.8E-03
1.3E-02
8.9E-05
3.2E-02
6.1E-03
1.2E-04
2.3E-04
4.3E-03
8.8E-06
2.0E-04
1.7E-02
1.9E-02
6.5E-03
9.2E-03

SCYL1
RPL35P9
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
SAA2
PKDCC
ZBTB1
SLC9B2
AKAP5
CTD.2176I21.2
RP11.15F12.1
AC079896.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
HARS
COBL
RP11.443B20.1
NBR1
PIGC

3.5E-03
1.9E-02
4.1E-05
9.3E-03
3.1E-03
2.2E-02
3.3E-03
1.1E-03
3.3E-02
7.5E-03

4.2E-02
1.3E-03

3.0E-02
1.4E-02
3.5E-03
1.1E-02
5.9E-03
1.9E-02

3.9E-02
8.0E-03
4.0E-02
1.6E-03
1.3E-03

1.5E-04
3.7E-04

1.8E-05
9.9E-04
2.2E-05
3.2E-02

1.4E-03
1.2E-03
2.3E-02

SCYL1
RPL35P9
PRM1
AP000769.8
RN7SL146P
CTD.3222D19.7
BTBD7P2
RABGGTA
SPATA21
GS1.410F4.5
RP11.732M18.2
SAA2
PKDCC
ZBTB1
SLC9B2
AKAP5
CTD.2176I21.2
RP11.15F12.1
AC079896.1
FAM162B
YTHDC2
LINC00926
CCDC179
RP11.84C13.2
HARS
COBL
RP11.443B20.1
NBR1
PIGC
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3.2E-03
1.7E-02
4.1E-05
1.4E-02
3.1E-03
1.4E-02
5.5E-03
6.3E-04
3.3E-02
3.9E-02
7.5E-03

4.2E-02
7.1E-03

3.0E-02
1.4E-02
3.2E-03
1.1E-02
5.9E-03
2.0E-02

1.0E-02
4.2E-02
1.6E-03
1.3E-03

1.6E-04
3.8E-04

1.8E-05
1.0E-03
1.3E-04
4.7E-02

1.6E-03
1.1E-03
2.4E-02

